Entries |
Document | Title | Date |
20080199890 | Methods of Determining Cellular Chemosensitivity - The present invention provides methods of determining cell sensitivity to a therapeutic agent. | 08-21-2008 |
20080199891 | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy - Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer. | 08-21-2008 |
20080213804 | Parallel Processing Fluidic Method and Apparatus for Automated Rapid Immunohistochemistry - A sample processing system that may be configured to achieve parallel or coincidental sample processing such as histochemical processing may involve a plurality of samples arranged for coincidental movement perhaps by use of angular microscopic slide movements to cause processing activity that may include repeated elimination and reapplication of a fluidic substance perhaps through the action of capillary motion in order to refresh a microenvironment adjacent to a sample such as a biopsy or other such sample. Snap in antibody and other substances may be included to ease operator actions and to permit location specific substance applications perhaps by including single container multiple chamber multiple fluidic substance magazines, linearly disposed multiple substance source, and primary antibody cartridges. Through refreshing of a microenvironment, depletion of the microenvironment is avoided and the time necessary for slide processing may be dramatically shortened from a more common 60 to 120 minutes to perhaps less than 15 minutes so as to permit use of such a system in an intraoperative or surgical environment such as recommended by the College of American Pathologists intraoperative guidelines or the like. Patients may thus avoid a need to be subjected to an additional surgical procedure when lab results become available to see if tumors or the like were fully removed in a prior procedure. | 09-04-2008 |
20080213805 | Method for Distinguishing Follicular Thyroid Adenoma (FTA) from Follicular Thyroid Carcinoma (FTC) - Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, Clorf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, Clorf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen. | 09-04-2008 |
20080220453 | Identification and isolation of squamous carcinoma stem cells - Squamous carcinoma stem cells (SCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and to form unique histological microdomains useful in cancer diagnosis. | 09-11-2008 |
20080220454 | Identification of genotype- selective anti-tumor agents - The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that are selectively toxic to engineered human tumorigenic cells. | 09-11-2008 |
20080220455 | p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR - p53-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a p53-induced nuclear protein that induces p53-dependent apoptosis by regulating p53 function through Ser 46 phosphorylation. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with p53-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating p53-mediated apoptosis. | 09-11-2008 |
20080227122 | P2Y PURINERGIC RECEPTOR EXPRESSION FOR IDENTIFYING PRENEOPLASTIC AND NEOPLASTIC STATES - The present invention relates to methods for identifying pre-neoplastic and neoplastic states in mammals and in particular to a method for identifying pre-neoplasia and neoplasia in cells and tissues based on differential expression of P2Y purineric receptors. | 09-18-2008 |
20080241862 | PROPIONYL AND BUTYRYL LYSINE MODIFICATIONS IN PROTEINS - While the identification of acetylated lysine residues on proteins is well-known, the modification of lysine residues through propionylation and butyrylation is not very well understood. A method for the identification and mapping of propionylated and butyrylated lysine residues has been developed. Anti-acetyllysine antibody, normally used to affinity purify a protein mixture based on the presence of acetylated lysine, can also be used to affinity purity proteins having propionylated and butyrylated lysine residues due to the structural similarity. The method involves searching protein databases to locate mass spectrometry datasets for those proteins purified by anti-acetyllysine antibody. The located spectra are manually reviewed to identify those peptides having propionyllysine and butyryllysine residues. These identified peptides are synthesized, with the lysine modifications added at the appropriate positions. The synthesized proteins are then analyzed with mass spectrometry and the resultant spectra are compared to those located in the protein databases to confirm the location of the lysine modifications. | 10-02-2008 |
20080248499 | Methods and Apparatus for the Isolation and Enrichment of Circulating Tumor Cells - Embodiments in accordance with the present invention relate to methods and apparatuses for concentrating and isolating Circulating Tumor Cells (CTCs) from body fluids. One embodiment of the present invention includes a micro-fabricated or nano-fabricated device having channels configured for separating and excluding. Embodiments in accordance with the present invention utilize features that reduce the hydrodynamic pressure experienced by the cells during the separation, isolation and concentration processes, and therefore reduce the likelihood of cell lysis or other damage to the cells. | 10-09-2008 |
20080248500 | Apolipoprotein A-II Isoform As A Biomarker For Prostate Cancer - The present invention provides a protein-based biomarker, ApoA-II isoform, that is useful in determining prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a biological sample as prostate cancer or non-prostate cancer. The ability of ApoA-II to detect disease in patients with a normal prostate-specific antigen (PSA) makes the biomarker of this invention useful in identifying indolent disease. The biomarker can be detected by SELDI mass spectrometry, HPLC, PAGE and Western blotting. | 10-09-2008 |
20080248501 | Methods of Diagnosing Ovarian Cancer and Kits Therefor - A method for the diagnosis of ovarian cancer comprising providing a biological sample from a subject (subject sample), and detecting the expression level of each of the markers FGF-2, CA 125 and IL-18 in the subject sample A kit comprising means for detection of an expression level of each of the markers CA 125, FGF-2 and IL-18 in a biological sample from a subject (subject sample), and instructions to use said markers in a method of the present invention. | 10-09-2008 |
20080254488 | Cancer Test - The CD133 marker has been found to be diagnostic of malignant lung cancers. Tests and kits to show such cells and uses for such cells are disclosed. | 10-16-2008 |
20080254489 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 10-16-2008 |
20080261243 | Detection of Elevated Levels of Her-2/Neu Protein on Circulating Cancer Cells and Treatment - The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN). | 10-23-2008 |
20080261244 | Compositions And Methods For Treating And Diagnosing Pancreatic Cancer - The present invention relates to the field of oncology and provides novel compositions and methods for diagnosing and treating pancreatic cancer. In particular, the present invention provides pancreatic cancer stem cells useful for the study, diagnosis, and treatment of solid tumors. | 10-23-2008 |
20080261245 | ANTIBODIES, INCLUDING FV MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE - Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin. | 10-23-2008 |
20080261246 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA. | 10-23-2008 |
20080268473 | Adamts-7 as a Biomarker for Cancers of Epithelial Origin - ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient. | 10-30-2008 |
20080274481 | Methods for diagnosing ovarian cancer - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry, immunoassay, or other means. | 11-06-2008 |
20080280309 | Monoclonal antibodies and uses thereof - The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided. | 11-13-2008 |
20080286814 | Biomarkers for Detecting Cancer - The disclosure features, inter alia, a variety of biomarkers (e.g., biomarker peptides), compositions, and kits for use in methods for diagnosing a cancer. The biomarkers can be used, e.g., in methods for detecting a cancer in a subject. In addition, the disclosure also features methods of selecting a therapy for, and/or administering a therapy (e.g., a therapy comprising an anti-cancer agent) to, a subject having a cancer. | 11-20-2008 |
20080286815 | SPECTROPHOTOMETRIC ASSAY FOR HUMAN HISTONE DEACETYLASE 8 - The present invention relates to the development of a novel assay for determining the activity of human histone deactylase 8 (HDAC8). As shown in FIG. | 11-20-2008 |
20080299589 | Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers - The invention disclosed herein provides methods for the examination and/or quantification of the PI3K/Akt and Ras/MAPK biochemical pathways that are disregulated in pathologies such as cancers of the prostate and gliomas. The invention disclosed herein further provides reagents and kits adapted for performing such methods. | 12-04-2008 |
20080299590 | SHC protein-related methods and compositions - The present invention provides a method for predicting whether an individual (e.g., patient) will benefit from a (one or more) treatment for cancer comprising determining the amount of p66-Shc present in cancerous cells or precancerous cells (e.g., displasia) of the individual. If the amount of p66-Shc present in the cells of the individual is lower than the amount of p66-Shc in a control, then the individual will likely benefit from the treatment. | 12-04-2008 |
20080305502 | Method of Screening Baff Suppressor or Inhibitor - A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody. | 12-11-2008 |
20080311594 | USE OF FIBROBLAST GROWTH FACTOR 7 (Fgf7) AND OF THE RECEPTOR Fgfr2b AS BIOMARKERS - The use of fibroblast growth factor Fgf7 and of the corresponding receptor Fgfr2b as biomarker candidates for the progesterone receptor antagonist 11β-(4-acetylphenyl)-17B-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one, also known under the designations ZK230211 or ZK-PRA, of the formula | 12-18-2008 |
20090011438 | Collagen VI and Cancer - Methods of determining whether a cancer is progressing by measuring surface-bound collagen VIα3 are provided. Also provided are methods of identifying hyperplasia in a tissue by measuring surface-bound collagen VIα3. Additionally, methods of identifying carcinoma in a tissue by measuring surface-bound collagen VIα3 are provided. Further provided are methods of imaging carcinoma in a tissue by staining the tissue with a specific binding partner to collagen VIα3. Methods of treating a cancer by preventing binding of collagen VIα3 onto cells of the cancer are additionally provided. | 01-08-2009 |
20090011439 | Prognosis and Therapy Predictive Markers and Methods of Use - Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention. | 01-08-2009 |
20090011440 | Receptor Tyrosine Kinase Signaling Pathway Analysis For Diagnosis And Therapy - The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis. | 01-08-2009 |
20090011441 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. | 01-08-2009 |
20090017472 | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFalpha INHIBITORS IN AUTOIMMUNE DISORDERS - The invention provides methods for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis. The methods involve assaying for expression of one or more biomarkers in the subject that are predictive of responsiveness to TNFα inhibitors. A preferred biomarker of the invention is CD11c. The methods can further comprise selecting a treatment regimen with a TNFα inhibitor in an autoimmune disorder subject based upon expression of the biomarker(s) in the subject. The methods can further comprise administering a TNFα inhibitor to the subject according to the selected treatment regimen. Kits that include means for measuring expression of one or more biomarkers that are predictive of responsiveness to TNFα inhibitors for an autoimmune disorder are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting an autoimmune disorder subject for treatment with a TNFα inhibitor are also provided. | 01-15-2009 |
20090017473 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 01-15-2009 |
20090017474 | SYSTEMS AND METHODS FOR DETECTING ABNORMAL CELLS - Systems and methods of interrogating clusters of cells for two or more biological markers that do not, or rarely, occur in the same cell during normal cellular growth, development and function, to indicate the existence of cells that are part of a local area where a pre-neoplastic or neoplastic lesion may be present. The relationship among cells is maintained while interrogating the clusters of cells to facilitate the examination and determination of the existence of possible dysplasia. | 01-15-2009 |
20090023160 | Antibodies specific for CYP1B1 - Antibodies that can specially bind to cytochrome P450 CYP1B1 and methods of making them are disclosed, in particular antibodies that bind to amino acid sequence VNQWSVNHDPVKWPN or PExFDPARFLDKDGy, where x is D or N and y is L or F, or an antigenic fragment thereof. The antibodies can be used in the diagnosis or treatment of cancers linked to enhanced CYP1B1 expression, including breast cancer, prostate cancer, colorectal cancer, liver cancer and ovarian cancer. | 01-22-2009 |
20090029393 | METHOD FOR PREPARING ANTIBODIES SELECTIVE FOR ACTIVATING FC RECEPTORS - The present invention relates to a method for preparing an antibody selective for activating antibody Fc region receptors (FcRs) comprising an ITAM motif or motifs (immunoreceptor tyrosine-based activation motif), comprising the steps of obtaining monoclonal antibodies from a hybridoma, from a heterohybridoma or from any animal, plant or human cell line, replacing each of the His 310 and His 435 residues (Cabat numbering) of the Fc region of said antibody with a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and then selecting the antibodies for which the binding to inhibitory FcRs comprising ITIM motifs (immunoreceptor tyrosine-based inhibition motif) is decreased by at least 30%, preferably by at least 50%, 70%, 80% or else by at least 90% relative to the same antibody having a natural Fc region. The present invention also relates to the use of an antibody derived from the method of the invention in the production of a medicament for use in particular in the treatment of cancer and of infectious pathologies. | 01-29-2009 |
20090035792 | DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 02-05-2009 |
20090047689 | AUTOANTIGEN BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG ADENOCARCINOMA - Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment. | 02-19-2009 |
20090068684 | Serine and threoninephosphorylation sites - The invention discloses 345 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 03-12-2009 |
20090068685 | Method of Identifying Biomarkers in Human Serum Indicative of Pathologies of Human Lung Tissues - A method of identifying altered biomarker expression levels in a human serum specimen to diagnose asthma or non-small celled lung cancers in humans. The existence of asthma or non-small celled lung cancers in a patient can be determined by subjecting a blood sample from the patient to a simple blood test to determine the expression levels of certain specific biomarkers. The expression levels of the specific biomarkers are compared to ranges of expression levels for the same biomarkers which are indicative of individuals known to have asthma, non-small cell lung cancers, or neither. Comparing the expression levels will determine the existence or non-existence of asthma or non-small cell lung cancer. | 03-12-2009 |
20090075301 | Diagnostic Marker - A diagnostic marker is composed of particles that have a diameter of from 1 nm to 100 μm, the particles possessing on their surfaces a site that has a high specific bonding ability to a specific antigen residing on the mucosa of digestive cancers and a site that has a low bonding ability to the mucosa of digestive organs, and further incorporating an identification material. | 03-19-2009 |
20090075302 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-19-2009 |
20090081709 | Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors - The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided. | 03-26-2009 |
20090081710 | Method for Cancer Prognosis Using Cellular Folate Vitamin Receptor Quantification - The invention relates to a method for determining a prognosis for a cancer by quantifying vitamin receptor expression on the cancer cells. The method comprises the steps of quantifying vitamin receptor expression on the cancer cells, and determining a prognosis for the cancer. The invention also relates to methods and kits for determining the presence of vitamin receptors on cancer cells to select patients that should be treated with a therapy that utilizes vitamin receptor targeting and to develop a treatment regimen for such patients. The invention further relates to kits for performing the methods. | 03-26-2009 |
20090098581 | Tyrosine phosphorylation sites - The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 04-16-2009 |
20090104631 | PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 04-23-2009 |
20090111127 | Surface Receptor Complexes as Biomarkers - The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis. | 04-30-2009 |
20090117595 | PRIMARY CENTRAL NERVOUS SYSTEM TUMOR SPECIFIC BEHAB ISOFORMS - The present invention comprises compositions and methods related to a glycosylation-variant BEHAB protein, poly-sialyated full-length BEHAB, and methods of use thereof. | 05-07-2009 |
20090123948 | Autoantibody detection for cancer diagnostics - The present invention relates to compositions and methods for the detection of anti-ECPKA autoantibodies in a biological sample, and to the use of such compositions and methods in the diagnosis of cancer in humans and non-human mammals. | 05-14-2009 |
20090123949 | METHODS FOR DETERMINING THE PROGNOSIS FOR CANCER PATIENTS USING TUCAN - The invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) comparing the level of TUCAN in the sample to a reference level of TUCAN, wherein a low level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) classifying the patient as belonging to either a first or second group of patients, wherein the first group of patients having low levels of TUCAN is classified as having an increased likelihood of survival compared to the second group of patients having high levels of TUCAN. | 05-14-2009 |
20090123950 | Generation And Profiling Of Fully Human Hucal Gold.RTM.-Derived Therapeutic Antibodies Specific For Human CD38 - The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | 05-14-2009 |
20090130693 | NOVEL BIOMARKERS FOR DIAGNOSIS AND/OR PROGNOSIS OF NEOPLASIAS IN ANIMALS - The invention is generally applicable in the field of biomedical engineering, and specifically relates to a method for diagnosis and/or prognosis of neoplasias in animals. The invention further relates to a diagnostic/prognostic kit associated to such method, a reagent for the preparation of such kit and the use of particular biomarkers in such method and/or kit. The method comprises at leas the steps of: drawing at least one sample from the patient and determining the amount of a biomarker in said at least one sample drawn from the patient. The biomarker is a protein released by pancreatic cells. | 05-21-2009 |
20090130694 | MAC-2BP as a Marker for the Diagnosis of Gastric Cancer - Disclosed is a diagnostic kit for gastric cancer. It comprises an agent capable of detecting and quantitatively assaying the gastric cancer marker Mac-2BP (Mac-2 binding protein). Also, a method for detecting the gastric cancer marker using the kit is disclosed. | 05-21-2009 |
20090130695 | GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof - The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S. | 05-21-2009 |
20090148868 | JAB1 AS A PROGNOSTIC MARKER AND A THERAPEUTIC TARGET FOR HUMAN CANCER - Methods of diagnosing and prognosticating the development of human cancers, such as breast cancer, colon cancer, and pancreatic cancer, are provided. The diagnostic and prognostic methods include the detection and/or quantifying of the amount of expression of JAB1 in human cells, particularly in relation to the amount of p27 or c-Jun. In addition, methods for reducing the expression of JAB1 protein in cells and inhibiting its interaction with p27 or c-Jun, for example, are provided. | 06-11-2009 |
20090155820 | ASC as a marker for colorectal cancer - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein ASC (apoptosis-associated speck-like protein containing a caspase-associated recruitment domain) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring ASC in said sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of colorectal cancer. | 06-18-2009 |
20090155821 | ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ASSAY - Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium. | 06-18-2009 |
20090162874 | METHOD FOR SCREENING ANTICANCER SUBSTANCES, SET OR KIT FOR IMPLEMENTING SAID METHOD - A method for screening anticancer substances comprising the following steps:
| 06-25-2009 |
20090170130 | Phosphospecific Chemokine Receptor Antibodies - The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods. | 07-02-2009 |
20090170131 | Agents for Imaging Apoptosis - Compositions, and methods of using such compositions, having the following Formula (I) or salt, ester, or hydrate thereof, wherein R | 07-02-2009 |
20090170132 | Methods for detecting colon carcinoma - The present invention provides methods for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence or absence of or determining the amount of one or more carcinoma associated markers. Further, the present invention provides methods for determining whether a tissue should be surgically resected and for determining the territorial extent of resection. The carcinoma markers may be those provided in FIG. | 07-02-2009 |
20090191575 | TUMOR MARKER AND METHOD FOR DETERMINATION OF THE OCCURRENCE OF CANCEROUS DISEASE - The present invention provides a tumor marker and a method capable of identifying the morbidity of colon cancer. A tumor marker including a protein identified from a colon cancer tissue. A method for identify the morbidity of colon cancer using the tumor marker. The method includes: measuring the level of the protein in a sample derived from a person of interest who should be examined to identify the morbidity of colon cancer; and comparing the measured level to the normal level of the protein, wherein a higher or lower measured level than the normal level is used as one indicator indicating that there is a high possibility that the person of interest has colon cancer. | 07-30-2009 |
20090197285 | Lung Cancer Diagnostic Assay - A diagnostic assay for determining presence of lung cancer in a patient depends, in part, on ascertaining the presence of an antibody associated with lung cancer. The assay predicted lung cancer prior to evidence of radiographically detectable cancer tissue. | 08-06-2009 |
20090203050 | MOLECULAR SIGNALING PATHWAYS TRIGGERED BY RITUXIMAB: PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC USES - The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-κB, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules. | 08-13-2009 |
20090203051 | TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY - Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers. | 08-13-2009 |
20090208980 | METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION - An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma. | 08-20-2009 |
20090215088 | Tagged Ligands For Enrichment of Rare Analytes From A Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 08-27-2009 |
20090215089 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 08-27-2009 |
20090215090 | ERCC1 EXPRESSION IN PREDICTING RESPONSE FOR CANCER CHEMOTHERAPY - The present invention concerns an in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy, said method comprising the step of the measurement of the ERCC1 protein by immunohistochemistry in a formalin-fixed paraffin-embedded tumor sample. | 08-27-2009 |
20090215091 | DIAGNOSTIC PANEL OF CANCER ANTIBODIES AND METHODS FOR USE - The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2/neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid. | 08-27-2009 |
20090221004 | Caspase-cleavage anti-keratin antibodies for detection of apoptosis - The present invention relates to the field of detecting and quantifying apoptosis. In one aspect, the invention is directed to an isolated monoclonal or polyclonal antibody that specifically recognizes caspase-generated products of K18 or K19 but does not react with intact K18 or K19. The antibody typically reacts with the cleavage site of K18 or K19 at Asp237. The binds to the epitope common to caspase-cleaved K18 and K19-(T/S)VEVD- and the Asp-proximal valine is essential for antibody recognition. | 09-03-2009 |
20090239247 | MN and Hypoxia - The MN/CA IX protein is identified herein as a hypoxia marker. The MN/CA9 gene promoter is characterized, and the location of the HIF-1 binding site within the MN/CA9 promoter is identified. Further, the hypoxia inducibility of the MN/CA9 gene and the uses of such inducibility are disclosed. In one aspect, the invention provides diagnostic/prognostic tools for determining the presence of hypoxia in a tissue in a vertebrate, preferably a human, and for measuring the relative degree of hypoxia in said vertebrate. In another aspect, the invention provides methods using tumor biopsies to predict the radioresistance of a preneoplastic/neoplastic tissue in a vertebrate subject, preferably a human patient, for diseases in which MN/CA IX levels can be used to indicate radiobiologically relevant tumor hypoxia. Such predictive methods can be used as an aid in patient therapy selection. | 09-24-2009 |
20090269787 | Monoclonal Antibody to CD166 and Method for Production Thereof - CD166 is a cell adhesion molecule belonging to an immunoglobulin superfamily that is expressed in an excessive amount on the tumor surface. If an monoclonal antibody specifically binding to the CD166 is obtained, it becomes possible to suppress growth of tumor cells, detect the cells, and supply a therapeutic drug thereto specifically. However, because the CD166 proteins are very similar to each other among mammals, it was not possible to obtain an antibody to human CD166, by immunizing, for example, mice with the human CD166. | 10-29-2009 |
20090275057 | Diagnostic markers predictive of outcomes in colorectal cancer treatment and progression and methods of use thereof - Colorectal cancer patients with operable tumors must decide whether to receive adjuvant therapy after surgical resection in order to reduce their chances of recurrence. Current clinical guidelines are crudely based on the stage of the disease, as well as a few other clinicopathologic features. The instant invention integrates data from these clinicopathologic features with data on multiple biomarkers using advanced informatic methods to provide a far more accurate prediction of recurrence than the current guidelines. The instant invention consists of a panel of biomarker assays plus an algorithm into which the scored biomarker data, as well as standard clinicopathologic data, is entered. A tumor sample from an individual patient is submitted for test, and an individualized report is produced with a prognostic score that accurately reflects the patient's risk of recurrence. This helps guide the patient and his/her oncologist in their choice of whether to receive adjuvant treatment. Low-risk patients are spared the unnecessary toxicities associated with cytotoxic treatments, and high-risk patients are given the best chance for a cure, maximizing both life expectancy and quality of life. | 11-05-2009 |
20090280511 | Methods for selecting candidate peptides presented on the surface of cancer cells following their binding to MHC class I molecules - An objective of the present invention is to provide methods for selecting candidate peptides presented on the surface of cancer cells following binding to MHC class I molecules, wherein the peptides are involved in the stimulation of T cell immunity (cellular immunity). The present inventors discovered a new principle of MHC I-mediated antigen presentation in which a T cell antigen epitope is more efficiently presented on MHC I molecules when it is positioned at the N-terminal side than when positioned at the C-terminal side. | 11-12-2009 |
20090280512 | TUMOR MARKER FOR RENAL CANCER AND METHOD FOR DETERMINATION OF OCCURRENCE OF RENAL CANCER - The present invention provides a tumor marker more highly specific to renal cancer. The present invention provides a method for identifying the morbidity of renal cancer. A tumor marker for renal cancer comprising proteins identified from renal cancerous tissue. A method for identifying the morbidity of renal cancer by using the tumor marker for renal cancer. The method comprises measuring the level of the protein in a sample derived from a person of interest who is to be examined to identify the morbidity of renal cancer; and comparing an obtained measured level to a normal level of the protein, wherein an upregulation or a downregulation of the obtained measured level compared to the normal level is used as one of indexes indicating that there is a high possibility that the person of interest has renal cancer. | 11-12-2009 |
20090286265 | Cripto Blocking Antibodies And Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 11-19-2009 |
20090298097 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER - The present invention is directed to new ways to diagnosis lung cancer, especially at an early clinical stage. In addition, prognosis and the monitoring of therapeutic agents or other treatments, for lung cancer patients, can be accomplished with the disclosed methods. The methods also find use in allowing the assessment by pre-clinical animal efficacy studies to screen for the useful of therapeutic agents for treating lung cancer. | 12-03-2009 |
20090311721 | ASBESTOS EXPOSURE, PLEURAL MESOTHELIOMA, AND SERUM OSTEOPONTIN LEVELS - The present invention provides diagnostic methods based on the serum levels of osteopontin. | 12-17-2009 |
20090317836 | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject - Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of metastatic cancer or early stage cancer. | 12-24-2009 |
20090317837 | CANCER DIAGNOSIS BASED ON LEVELS OF ANTIBODIES AGAINST GLOBO H AND ITS FRAGMENTS - A cancer diagnostic method using a glycan array that contains Gb5 and Globo H, Bb2, Bb3, and/or Bb4. | 12-24-2009 |
20090325199 | NANOSTRUCTURES FOR POLARIZED IMAGING AND RECEPTOR/LIGAN QUANTIZATION: BREAKING THE DIFFRACTION LIMIT FOR IMAGING - The present invention relates to affinity biosensing using polarization of light scattering of aggregated noble metallic nanostructures to determine concentration of an analyte in a test sample. This new sensing system utilizes the changes in polarized plasmonic scattering from nanostructures as the nanostructures aggregate due to binding of the analyte to a binding partner attached to the surface of the metallic nanostructure. | 12-31-2009 |
20090325200 | POLYPYRIMIDINE-TRACT BINDING PROTEIN (PTB) AS A BIOMARKER AND TARGET FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides a method of diagnosing cancer in a mammalian subject comprising measuring the level of polypyrimidine-tract binding protein (PTB) in a tissue sample obtained from the subject. An elevated level of PTB in the sample comparing to a normal control is indicative the subject is positively diagnosed with cancer. The present invention furthers provides a method for inhibiting proliferation of a mammalian cancer cell. The method comprises suppressing the level of polypyrimidine-tract binding protein (PTB) in the cell. | 12-31-2009 |
20090325201 | Biomarkers for Detection and Diagnosis of Head and Neck Squamous Cell Carcinoma - Novel, sensitive and specific markers and methods for diagnostics and monitoring of head and neck squamous cell carcinoma (HNSCC) are provided. Kits and methods for the use of hyaluronic acid, hyaluronidase and CD44 to diagnose HNSCC are described. | 12-31-2009 |
20090325202 | Methods for Developing and Assessing Therapeutic Agents - Assays are provided that can effectively assess tumor response to one or more therapeutic agents. Preferred assays of the invention include assessment of posttranslation modification and expression of target proteins. | 12-31-2009 |
20100003705 | Cln101 Antibody Compositions and Methods of Use Alone and in Combination with Prostate Specific Antigen and Other Cancer Markers - This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln101 antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal. | 01-07-2010 |
20100009390 | MUTANT ANTIBODIES WITH HIGH AFFINITY FOR EGFR - This invention provides antibodies that have improved affinity for the epidermal growth factor receptor (EGFR). In addition, this invention provides microparticles and nanoparticles comprising a plurality of EGFR affinity moieties that are effectively internalized by cells expressing an EGFR. | 01-14-2010 |
20100015641 | DIAGNOSTIC AGENT FOR TUMOR - The present invention provides a diagnostic agent and a diagnostic kit for tumor such as lung cancer, cervical cancer, gastric cancer, breast cancer or the like, which comprise an antibody against MCAF1 or MCAF2; and a diagnostic method using an antibody against MCAF1 or MCAF2. | 01-21-2010 |
20100015642 | B7-H1 AND SURVIVIN IN CANCER - Methods of determining prognosis of a subject with cancer by assessing expression of B7-H1 and survivin in combination. | 01-21-2010 |
20100028914 | ASSESSING LUNG NODULES - This document provides methods and materials related to distinguishing malignant solitary pulmonary nodules from benign solitary pulmonary nodules in mammals (e.g., humans). | 02-04-2010 |
20100028915 | CIRCULATING TUMOR CELL ASSAY - Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided. | 02-04-2010 |
20100035281 | COMPOSITIONS AND METHODS FOR TISSUE-BASED PROTEIN TRUNCATION TEST FOR DISEASE DIAGNOSIS - Embodiments herein concern methods and compositions for diagnosing or predicting the onset of a genetic disorder In certain embodiments, the methods may include use of a rapid and inexpensive assay. In other embodiments, the assay utilizes a tissue sample from a subject to identify the state of a target protein known to associate with a genetic disorder In accordance with these embodiments, the target protein may have a DNA sequence change such as a mutation, deletion, insertion or substitution leading to generation of a termination codon and truncation of the protein. In some embodiments, a composition of an antibody directed to bind a protein associated with a disorder may be used to predict onset of the disorder or predict sensitivity of the disorder to therapeutic treatments. | 02-11-2010 |
20100041073 | TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of | 02-18-2010 |
20100041074 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-GRP78 ANTIBODY AS ACTIVE INGREDIENT - An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention aims to provide a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. | 02-18-2010 |
20100075344 | Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes - The invention relates to the diagnosis, monitoring, prognosis, and/or prediction of cancer utilizing the detection or measurement of glycan-protein interactions, particularly glycan-antibody interactions. The invention relates to carbohydrate-containing molecules that are utilized in bioanalytical systems, methods and kits for detecting neoplasia and methods related thereto and based thereon. In an exemplary embodiment glycans or glycopolymers are carried in an array, on beads or in a microfluidic system for diagnostic screening for risk of neoplasia, the existence of neoplasia in a patient, or for treatment monitoring. In such an embodiment, the bioanalytic system identifies binding interactions between molecules in a patient test sample (e.g., glycan compositions) and the glycans or glycopolymers. The glycan-binding compositions may be used to generate an immune response against cancer cell epitopes. Alternatively, antibody therapeutics can be developed that are useful for binding to glycan compositions on a cell surface. | 03-25-2010 |
20100075345 | METHOD OF SCREENING - A method of screening for a molecule which decreases apoptosis of a cell, comprising: i) combining the candidate molecule and an assay cell; and ii) determining the change in survival of the assay cell in the presence of the molecule relative to a control. In one embodiment, the assay cell is treated with an apoptosis inducing agent prior to or between steps i) and ii). In one example, the treating agent reduces the level or activity of a pro-survival member of the Bcl-2 protein family, such as Bcl-x | 03-25-2010 |
20100081151 | BIOMARKERS FOR EARLY DETECTION OF OVARIAN CANCER - Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules. | 04-01-2010 |
20100086949 | RETENTATE CHROMATOGRAPHY AND PROTEIN CHIP ARRAYS WITH APPLICATIONS IN BIOLOGY AND MEDICINE - This invention provides methods of retentate chromatography for resolving analytes in a sample. The methods involve adsorbing the analytes to a substrate under a plurality of different selectivity conditions, and detecting the analytes retained on the substrate by desorption spectrometry. The methods are useful in biology and medicine, including clinical diagnostics and drug discovery. | 04-08-2010 |
20100093002 | Diagnosis and treatment of malignant neoplasms - The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex. | 04-15-2010 |
20100093003 | METHODS TO IMPAIR HEMATOLOGIC CANCER PROGENITOR CELLS AND COMPOUNDS RELATED THERETO - Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3Rα or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics. | 04-15-2010 |
20100120072 | DETECTION OF ELEVATED LEVELS OF HER-2/NEU PROTEIN FROM NON-ISOLATED CIRCULATING CANCER CELLS AND TREATMENT - The expression of Her-2/neu protein on circulating cancer cells in a sample of blood or peripheral blood mononuclear cells (PBMCs) is detected by performing a sensitive Her-2/neu immunoassay. There is no need to isolate the cancer cells before performing the immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN), lapatinib, CP-724,714, NKI-272, and BMS-599626 | 05-13-2010 |
20100129834 | AUTOIMMUNE REGULATION OF PROSTATE CANCER BY ANNEXIN A3 - The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance. | 05-27-2010 |
20100136583 | Method for Diagnosing Tumors by Measuring the Level of Apolipoprotein A-IV - Method for diagnosing a tumor in an individual comprising the following steps: —measuring the amount of apolipoprotein A-IV (ApoA-IV) in a body fluid sample or tissue sample of an individual, —comparing the measured amount of ApoA-IV in said sample with a reference value, wherein the reference value is the ApoA-IV content in a sample derived from an individual without a tumor, and —diagnosing a tumor if the ApoA-IV content in the sample is decreased compared to the reference value. | 06-03-2010 |
20100136584 | METHODS FOR USING ANTIBODIES AND ANALOGS THEREOF - Camelid and shark single-domain heavy chain antibodies lacking the light chains, and their analogs are disclosed. Methods for using the antibodies and their analogs to detect antigens are disclosed. Methods to derivatize such antibodies and analogs to develop diagnostic assays are described. Also provided are kits, and methods of using such diagnostics assays. | 06-03-2010 |
20100143947 | REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY - Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer. | 06-10-2010 |
20100143948 | CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS - The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient. | 06-10-2010 |
20100151501 | Forms of Prostate Specific Antigens and Methods for their Detection - Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer. | 06-17-2010 |
20100184099 | Reagents And Methods For Cancer Prognosis And Pathological Staging - This invention provides reagents and methods for assessing tumor progression using tissue or tumor cell-containing samples from an individual. The invention also provides reagents and methods for assessing response to chemotherapy. | 07-22-2010 |
20100184100 | Tyrosine Kinome - Protein kinases are important signaling molecules involved in tumorigenesis. Mutational analysis of the human tyrosine kinase gene family (98 genes) identified somatic alterations in −20% of colorectal cancers, with the majority of mutations occurring in NTRK3, FES, GUCY2F and a previously uncharacterized tyrosine kinase gene called MCCK/MLK4. Most alterations were in conserved residues affecting key regions of the kinase domain. These data represent a paradigm for the unbiased analysis of signal transducing genes in cancer and provide useful targets for therapeutic intervention. | 07-22-2010 |
20100196931 | DETERMINATION OF RESPONDERS TO CHEMOTHERAPY - The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used. | 08-05-2010 |
20100216168 | METHODS FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE - The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-β1, TGF-β2, TGF-β3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients. | 08-26-2010 |
20100216169 | Method for Detecting and Prognosing Pre-Cancerous Cells Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine - Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy. | 08-26-2010 |
20100221754 | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer. | 09-02-2010 |
20100233732 | Methods of Determining Patient Response By Measurement of HER-2 Expression - Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial. | 09-16-2010 |
20100233733 | MULTIPLE MECHANISMS FOR MODULATION OF THE PI3 KINASE PATHWAY - An embodiment of the present invention is a method for measuring the post translational states and expression levels of proteins in the PI3K and/or mTor for use in diagnosis, prognosis and drug screening applications. | 09-16-2010 |
20100248266 | PURINERGIC (P2X) RECEPTORS IN EXTRA-CELLULAR BODY FLUID - The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to antibodies for the diagnosis of a disease or condition, especially cancer. | 09-30-2010 |
20100261204 | Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers - The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL). | 10-14-2010 |
20100267058 | CIRCULATING RET RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase. | 10-21-2010 |
20100273190 | PKHDL1, A HOMOLOG OF THE AUTOSOMAL RECESSIVE KIDNEY DISEASE GENE - Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided. | 10-28-2010 |
20100273191 | METHODS OF DIAGNOSING CANCER - A method of diagnosing cancer or a pre-malignant lesion is disclosed. The method comprises determining a level of CD24 expressed on peripheral blood cells of a subject in need thereof, wherein the level of CD24 above a predetermined threshold is indicative of the cancer or the pre-malignant lesion. | 10-28-2010 |
20100279320 | High-throughput cell transfection device and methods of using thereof - Transfecting biology cells with nucleic acid molecules (DNA, siRNA) is an essential prerequisite in elucidating how genes function in complex cellular context and how their activities could be modulated for therapeutic intervention. Traditionally studies are carried out on a low throughput gene-by-gene scale, which has created a huge bottleneck in functional genomic study and drug discovery. Development of high-throughput cell transfection technology will permit functional analysis of massive number of genes and how their activities could be modulated by chemical or biological entities inside cells. This invention describes design, construction of device and apparatus for high throughput effective cell transfection. Procedures and protocols for using the device and apparatus are also described in the application. Novel methods of using the device in cell-based assays are also disclosed. | 11-04-2010 |
20100279321 | METHODS AND APPARATUS FOR THE ISOLATION AND ENRICHMENT OF CIRCULATING TUMOR CELLS - Embodiments in accordance with the present invention relate to methods and apparatuses for concentrating and isolating Circulating Tumor Cells (CTCs) from body fluids. One embodiment of the present invention includes a micro-fabricated or nano-fabricated device having channels configured for separating and excluding. Embodiments in accordance with the present invention utilize features that reduce the hydrodynamic pressure experienced by the cells during the separation, isolation and concentration processes, and therefore reduce the likelihood of cell lysis or other damage to the cells. | 11-04-2010 |
20100279322 | Direct detection of intracellular fluorescently tagged cells in solution - A method of detecting target cells and pathogens in a test sample concentrates to target cells in solution by filtering or capturing the target cells on a solid support. The target cells are tagged with a fluorescent dye and dispersed in a solution or suspension. The resulting solution or suspension are introduced to a fluorometer to specifically identify and quantitate the target cells. The target cells can be lysed or whole when introduced to the fluorometer. | 11-04-2010 |
20100279323 | METHOD FOR PREDICTING RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPY - This invention provides methods for determining or predicting response to cancer therapy in an individual. | 11-04-2010 |
20100291592 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND - The sensitivity of a tumor cell to a sulfonamide compound or the anti-tumor effect of a sulfonamide compound can be examined by determining the expression level of EGFR1 in the tumor cell and employing the variation in the EGFR1 expression level as a measure. Thus, a method for determination of the sensitivity of a tumor cell to a sulfonamide compound; a method for determination of the anti-tumor effect of a sulfonamide compound; and a test kit for use in these methods are provided. | 11-18-2010 |
20100291593 | METHOD OF IDENTIFYING DIAGNOSTIC REAGENTS - Disclosed herein are methods for identifying diagnostic reagents (e.g., antigen-binding molecules, such as antibodies) that are useful, for instance, as primary diagnostic, prognostic, and/or predictive (e.g., companion diagnostic) reagents in a disease state, such as cancer. | 11-18-2010 |
20100291594 | ErbB Surface Receptor Complexes as Biomarkers - The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis. | 11-18-2010 |
20100297675 | SUBSTRATE AND METHOD FOR CULTURING BREAST CELLS - A cell culture article includes a porous substrate having a plurality of pores and a plurality of interstices in communication with the pores. At least some of the plurality of pores and interstices are sufficiently large for two or more mammary epithelial cells to cluster within the pores or interstices. Non-malignant mammary epithelial cells or breast cancer cells may not attach strongly to the substrate surface, which may encourage cell-cell interaction. In many cases, the article is desirably free of components of unknown origin. The articles may be capable of maintaining culture of malignant and non-malignant mammary epithelial cells and allowing for development of in vivo-like morphologies or characteristics of such cells. | 11-25-2010 |
20100311083 | METHOD FOR DETERMINING THE THERAPEUTIC EFFECTIVENESS OF SUBSTANCES - The present invention relates to a method for determining the therapeutic efficacy of substances containing as agent at least one therapeutically effective, biotechnologically generated protein and/or peptide. The invention further relates to a kit and a biochip for conducting the method according to the present invention. | 12-09-2010 |
20100311084 | METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS - The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to a monoclonal EGFR antibody, such as cetuximab. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with a monoclonal EGFR antibody that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the monoclonal EGFR antibody during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen). | 12-09-2010 |
20100323370 | METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS - The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations. | 12-23-2010 |
20100330593 | METHODS AND COMPOSITIONS FOR DIAGNOSING NEOPLASTIC DISEASE - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 12-30-2010 |
20110003321 | Monitoring of Intercellular Mitochondorial Polarization - An object is a method of detecting changes in mitochondrial polarized state in a living cell. | 01-06-2011 |
20110008803 | ASSAYS FOR NON-APOPTOTIC CELL DEATH AND USES THEREOF - The invention relates to methods for identifying agents, which induce oxidative cell death in a tumor cell. The invention further relates to methods for identifying tumor cells, which are sensitive to agents that induce oxidative cell death. The invention also relates to methods for identifying subjects who are suffering from tumors, which are sensitive to agents that induce oxidative cell death. | 01-13-2011 |
20110014636 | METHOD OF DETECTING LEUKEMIC CELL - [Problems] To provide a marker which is useful in diagnosing leukemia and a method of using the same. | 01-20-2011 |
20110014637 | Method For Determining The Sensitivity Of Patients Suffering From A Cancer Disease To Biological Therapy - The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor. | 01-20-2011 |
20110020844 | Quantitative Zap-70 Assay - An quantitative ZAP-70 assay is provided, with ZAP-70+ and ZAP-70− controls, normal human blood controls, an improved antibody with better signal to noise ratio, and using the median MEFL that is calibrated using a standard curve. | 01-27-2011 |
20110027808 | METHODS AND KITS FOR DETECTING TUMOR-SPECIFIC FUSION PROTEINS - The invention relates to the field of cancer diagnosis and the application of diagnostic techniques in pathology and hematology. Specifically, the invention relates to improved flow cytometric techniques, and kits related thereto, for the detection of chromosomal aberrations and the detection of tumor specific gene products exclusively expressed by tumor cells. | 02-03-2011 |
20110027809 | METHOD FOR EVALUATION OF DEGREE OF MALIGNANCY OF TUMOR CELL - Disclosed is a method for evaluating the degree of malignancy of a tumor cell, which comprises: preparing a cell membrane fraction containing a receptor tyrosine kinase (RTK) from a sample containing the tumor cell; measuring the enzymatic activity of RTK in the cell membrane fraction in both the presence and absence of an RTK activity inhibitor; and comparing the results obtained in the presence of the RTK activity inhibitor with those obtained in the absence of the RTK activity inhibitor. | 02-03-2011 |
20110033875 | GLYCOPROTEIN CANCER BIOMARKER - The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics. | 02-10-2011 |
20110045501 | ST2-BASED DENGUE FEVER DIAGNOSTIC - A cytokine receptor family member (ST2), which has membrane bound as well as soluble bound forms, is elevated in patients during acute phase of dengue fever. Moreover, secondary cases of dengue fever had even more pronounced elevation of ST2 in serum in comparison to primary cases. One possible role of soluble ST2 might be to act as decoy for membrane bound ST2 signaling, therefore, promoting a proinflammatory response in secondary dengue infections. Alternatively, ST2 may act as a biomarker for endothelial damage such that ST2 may be useful in identifying severe dengue infections, specifically in dengue hemorrhagic fever. | 02-24-2011 |
20110045502 | Monoclonal Antibodies and Uses Thereof - The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided. | 02-24-2011 |
20110053185 | CULTURE BASED SCREENING ASSAY AND METHODS OF USE THEREOF TO IDENTIFY AGENTS WHICH MODULATE TUMOR DEVELOPMENT, INVASION AND DIFFERENTIATION - A 3D organotypic culture which phenocopies aggressive, invasive cancer and methods of use thereof are provided. | 03-03-2011 |
20110059469 | ANTI-CLDN6 ANTIBODY - The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent. | 03-10-2011 |
20110059470 | Tumor Microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis and treatment of tumors - Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject. | 03-10-2011 |
20110065130 | Diagnosing and Grading Gliomas Using a Proteomics - The present invention provides for a proteomic approach to grading gliomas, and for predicting patient survival. In addition to employing global protein expression patterns, such as by mass spectrometry, particular target proteins whose expression is altered in various gliomas can be used to predict the stage/classification of a glioma, as well as to indicate whether a given patient will be a short- or long-term survivor. | 03-17-2011 |
20110070598 | DETECTION OF ELEVATED LEVELS OF HER-2/NEU PROTEIN ON CIRCULATING CANCER CELLS AND TREATMENT - The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN). | 03-24-2011 |
20110081664 | MULTIPURPOSE MICROFLUIDIC DEVICE FOR MIMICKING A MICROENVIRONMENT WITHIN A TUMOR - The present application relates generally to a novel microfluidic device for the in it propagation of neoplastic cellagregates under conditions that mimic the physiological microenvironment found in tumors. The invention also describes methods of screening for therapeutic test agents and protocols that target proliferating and quiescent neoplastic cells within tumors. | 04-07-2011 |
20110081665 | Methods for making cancer prognoses based on subcellular localization of biomarkers - This invention provides a method of making a prognosis for a patient afflicted with a type of cancer such as colon cancer, based upon quantification of biomarkers such as thymidylate synthase in subcellular compartments. | 04-07-2011 |
20110091907 | METHOD FOR DETECTION OF LIVER CANCER CELL USING ANTI-GLYPICAN-3 ANTIBODY - The present invention relates to an in-vitro immunoassay method for detecting the presence of liver cancer cells in a subject. In the method of the present invention, antigen retrieval treatment based on heat-induced epitope retrieval method and antigen retrieval treatment based on protease-induced epitope retrieval method can be combined in the detection of glypican 3 antigen expression in liver cancer tissues to thereby detect the difference in the expression level or expression pattern of the glypican 3 antigen by immunohistochemical staining method. This enables samples, which has been determined by the conventional HIER method as highly expressing glypican 3, to be graded according to the expression level of glypican 3. | 04-21-2011 |
20110091908 | EARLY PROSTATE CANCER ANTIGEN-2: A NOVEL SERUM SPECIFIC MARKER FOR PROSTATE CANCER DETECTION - Early Prostate Cancer Antigen-2 (EPCA-2) is a prostate cancer biomarker, newly identified via proteomics-based examination of alterations in nuclear structure. EPCA-2 shows a higher overall specificity than PSA. Thus, an immunoassay based on antibodies against an epitope of EPCA-2 more accurately differentiates between confined and non-confined disease than PSA or Gleason score. | 04-21-2011 |
20110097743 | COMPOSITIONS AND METHODS OF DETECTING TIABS - The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects. | 04-28-2011 |
20110104718 | Analysis of Circulating Tumor Cells, Fragments, and Debris - The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods. | 05-05-2011 |
20110104719 | Methylarginine detection in cells and tissues - The present invention provides a method for identifying a biological sample as cancerous or normal by comparing the methylation status of arginine proteins in a test sample with the normal sample. A different level of binding or pattern of binding of antibodies which are specific for arginine containing proteins in their methylated state indicates an abnormal condition. | 05-05-2011 |
20110111435 | Detecting Cell Surface Markers - In one aspect, the present invention provides a method for detecting an expression level of a cell surface marker in a sample, comprising staining the sample with a reagent that labels the cell surface marker; obtaining an image of the stained sample; and determining a value for continuity of cell surface staining in the image, wherein the value is indicative of the expression level. | 05-12-2011 |
20110111436 | METHODS FOR ASSESSING CANCER FOR INCREASED SENSITIVITY TO 10-PROPARGYL-10-DEAZAAMINOPTERIN - Sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaaminopterin is assessed and patients are selected for treatment of cancer with 10-propargyl-10-deazaaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer. The polypeptide includes a member of a folate pathway polypeptide within a cell and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). | 05-12-2011 |
20110117576 | MCT-1, A HUMAN ONCOGENE - A novel gene, designated MCT-1 (for Multiple Copies in T-cell malignancy), is provided. A protein encoded by MCT-1, designated MCT-1, is also provided. Antisense oligonucleotides complementary to or homologous with a portion of MCT-1, substantially purified MCT-1, and methods of determining whether a cell is a tumor cell are also provided. The invention also includes monoclonal and polyclonal antibody preparations which bind with specificity to MCT-1. The invention further includes methods of determining whether a compound or a gene product is a modulator of MCT-1 expression, a method of reducing MCT-1 expression in a cell, and a method of conferring a growth advantage on a cell. | 05-19-2011 |
20110117577 | MICROFLUIDIC SYSTEM FOR TRAPPING AND DETECTION OF A BIOLOGICAL ENTITY IN A SAMPLE - According to embodiments of the present invention, a microfluidic system for detecting a biological entity in a sample volume is provided. The microfluidic system includes: an inlet configured to receive the sample volume; at least one microchannel in fluid communication with the inlet; a magnetic trapping region comprising the at least one microchannel; at least one detection region in fluid communication with the magnetic trapping region for detecting the biological entity to be detected; and at least one outlet in fluid communication with the at least one detection region. | 05-19-2011 |
20110124014 | Tissue Differentiation Method Based on Surface Enhanced Raman Scattering - This invention is related to sample preparation by a tissue differentiation method based on surface-enhanced Raman scattering (SERS) which enables fast and accurate pathological identification for tissue differentiation by means of surface-enhanced Raman scattering. The preparation of the sample includes homogenising a tissue sample by adding liquid nitrogen ( | 05-26-2011 |
20110124015 | APTAMER-BASED METHODS FOR IDENTIFYING CELLULAR BIOMARKERS - In this invention, a biomarker discovery method has been developed using specific biotin-labeled oligonucleotide ligands and magnetic streptavidin beads. In one embodiment, the oligonucleotide ligands are firstly generated by whole-cell based SELEX technique. Such ligands can recognize target cells with high affinity and specificity and can distinguish cells that are closely related to target cells even in patient samples. The targets of these oligonucleotide ligands are significant biomarkers for certain cells. These important biomarkers can be captured by forming complexes with biotin-labeled oligonucleotide ligands and collecting the complexes using magnetic streptavidin beads, whereupon the captured biomarkers are analyzed to identify the biomarkers. Analysis of biomarkers include HPLC-Mass Spectroscopy analysis, polyacrylamide gel electrophoresis, flow cytometry, and the like. The identified biomarkers can be used for pathological diagnosis and therapeutic applications. Using the disclosed methods, highly specific biomarkers of any kinds of cells, in particular cancer cells, can easily be identified without prior knowledge of the existence of such biomarkers. | 05-26-2011 |
20110124016 | Diagnosis and Treatment of Malignant Neoplasms - The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex. | 05-26-2011 |
20110136147 | Methods of identifying tumor associated glycoproteins - Novel methods to identify and characterize glycoproteins that are likely to be found in serum, and that will therefore provide more relevant disease markers than current methods are disclosed. The proteins that are likely to be found in serum are distinguished either by cleavage from the membrane or as potentially secreted proteins characterized by solubility in an aqueous phase. The methods disclosed also allow determination of differential glycosylation patterns of proteins that are likely to be found in serum from cells in various stages of disease. In addition, methods to identify novel therapeutic targets by identifying glycoproteins retained in diseased cells are disclosed. | 06-09-2011 |
20110136148 | Monoclonal Antibodies Against GMF-B Antigens, and Uses Therefor - The disclosure relates to monoclonal antibodies (mAbs) preferentially selective for soluble GMF-B (sGMF-B) antigens or for sGMF-B as well as other forms of GMF-B, hybridoma lines that secrete these antibodies or fragments thereof, and the use of such antibodies and antibody fragments to preferentially detect sGMF-B antigens, including for example those expressed by cancer cells or in patients with cancer or dementia. Other aspects of the present disclosure relate to antibodies that are specific to or demonstrate preferential binding to a soluble or secreted form of GMF-B. Yet other aspects relate to antibodies or antibody fragments that are capable of reducing the activity of GMF-B in at least one form, including a soluble form or a secreted form. The present disclosure further relates to monoclonal, chimeric antibodies and fragments thereof, processes for producing such antibodies and their fragments, and their therapeutic and diagnostic uses, including in the treatment and detection of cancer, e.g., human breast, ovary, head, neck, and brain, and dementia. Methods and kits for the immunodetection and immunotherapy of cells or samples which express sGMF-B antigens, e.g., from patient and non-patient samples, are also disclosed. | 06-09-2011 |
20110136149 | METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY - This invention provides methods for determining or predicting response to HER2-directed therapy in an individual. | 06-09-2011 |
20110136150 | Method of Determination of Receptor Binding Saturation Effected by Monoclonal Antibodies - The invention relates to the determination of the degree of membrane receptor binding by specific monoclonal antibodies. This method is notably beneficial for monoclonal antibodies that are used in targeted therapies in order to define a target effective dose (TED). Especially the invention relates to the determination of the saturation degree of receptor binding effected by an anti-EGFR antibody of interest. | 06-09-2011 |
20110165596 | Use of Carbamoyl Phosphate Synthetase 1 (Cps) as a Humoral Biomarker For the Diagnosis of Tumour Diseases and Chronic Inflammatory Intestinal Diseases - The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases. | 07-07-2011 |
20110223619 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 09-15-2011 |
20110236910 | PROSTATE CANCER BIOMARKER - The present invention relates to the field of prostate cancer. Particularly the invention relates to villin as a novel prostate biomarker. The invention further relates to compositions comprising anti-villin antibodies and use of these compositions for an improved detection of prostate cancer in a subject. | 09-29-2011 |
20110256556 | Humanized FcgR Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. | 10-20-2011 |
20110256557 | IDENTIFYING PARATHYROID HORMONE AGONISTS AND ANTAGONISTS - Provided herein are methods of screening for an agent that is a PTH agonist or antagonist. For example, provided is a method of screening for an agent that is a PTH agonist or antagonist, the method comprising contacting a cell with LRP6 and the agent to be screened, wherein the cell comprises a PTH1R, and determining the level of LRP6 binding to the PTH1R. An increased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH agonist. A decreased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH antagonist. Also provided are methods of treating a skeletal disorder in a subject, wherein the skeletal disorder is characterized by proliferative bone growth or reduced bone density. | 10-20-2011 |
20110256558 | MEASURING LEVELS OF FIBROCYSTIN-L - Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided. | 10-20-2011 |
20110275097 | DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS - The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments. | 11-10-2011 |
20110287450 | Methods For Diagnosing And Monitoring The Progression Of Cancer - Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided. | 11-24-2011 |
20110287451 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 11-24-2011 |
20110294142 | Multiply Fluorescently Labeled Calcium Phosphate-Protein Surfaces - Described herein are multiply-fluorescently-labeled calcium phosphate protein substrates composed of a base coated with a fluorophore-labeled calcium phosphate coating and further having a fluorescently-labeled protein. The multiply-fluorescently-labeled substrate may be a fluorescently labeled calcium phosphate surface having a fluorescently-labeled collagen. The substrates are useful in culturing and studying the activity of a variety of cells, including bone cells. The substrates described herein can be used for both solution- and image-based analysis of cultured cells. New methods for producing and using such coated substrates are also disclosed. | 12-01-2011 |
20110318757 | RECOMBINANT ANTI-MUC1 ANTIBODIES - Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analyses, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes. | 12-29-2011 |
20120009602 | Reagents and Methods for Assessment of Human Tumor Malignancy and for Targeting Malignant Tumor Cells - The disclosure relates to a monoclonal antibody, designated MAbH11B2C2, that binds specifically with a human hyaluronan-binding protein, designated H11B2C2. This protein can occur in two forms, one (apparently expressed by all malignant cells) having an apparent molecular size (as assessed by SDS-PAGE) of about 57 KDa, and another having an apparent molecular size of about 37 KDa. H11B2C2 is expressed by all malignant cell types tested, but does not appear to be significantly expressed by non-tumor cells. H11B2C2 can be used as a marker of malignant status, and MAbH11B2C2 can be used as a reagent for detecting malignant cells, for delivering agents to malignant cells, or both. | 01-12-2012 |
20120034626 | Neoplasia-Specific Autoantibodies and Methods - ENOX2 proteins are growth-related cell surface proteins expressed specifically by cancer cells; they catalyze NADH oxidation and protein disulfide-thiol interchange reactions. Taught herein are IgM class autoantibodies specific to ENOX2 (tNOX) in a variety of cancer patient sera. Early cancer patients produce these autoantibodies as a possible defense mechanism. Because ENOX2 is bound to autoantibodies in patients, it is unavailable to bind conventional ENOX2-specific antibodies in standard ELISA assays, but two-dimensional gel electrophoresis dissociates ENOX2 protein from autoantibodies, allowing detection. Probing ENOX2 using cancer sera as a source of ENOX2 autoantibodies followed by horseradish peroxidase-coupled anti-human IgM allows visualization and detection of the ENOX2 autoantibody. ENOX2 autoantibodies from breast cancer sera reacts with the ENOX2 isoforms from, e.g., lung and ovarian cancer patient sera. ENOX2 autoantibodies enable cancer screening based both on autoantibody detection and autoantibody dissociation to allow for standard ELISA development as well as therapy. | 02-09-2012 |
20120034627 | Diagnosis of benign and cancerous growths by measuring circulation tumor stem cells and serum annexina2 - Provided herein is a method for diagnosing/prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma. | 02-09-2012 |
20120034628 | STANDARDIZED EVALUATION OF THERAPEUTIC EFFICACY BASED ON CELLULAR BIOMARKERS - The present invention provides materials and methods for predicting the response of a disease state to a therapeutic agent. A targeting moiety specific for a biological marker is labeled with a reporter moiety and used to analyze cells characteristic of the disease state. The output of the reporter moiety, which may be fluorescence intensity, is compared to the output of reference standard analyzed under similar or identical conditions. The use of a reference standard allows biomarker reporting to be normalized. Biomarker values can then be correlated from sample to sample and from laboratory to laboratory based on quantitative calibration on a universal reference standard. | 02-09-2012 |
20120040375 | ANTI-MUC1 ANTIBODY - An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1. | 02-16-2012 |
20120058492 | Method and a Kit To Detect Malignant Tumors and Provide a Prognosis - A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth. | 03-08-2012 |
20120070848 | TUMOR CELL-DERIVED MICROVESICLES - The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer. | 03-22-2012 |
20120070849 | METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 03-22-2012 |
20120083005 | METHODS FOR IN VITRO CANCER CELL DETECTION, DIAGNOSIS AND THERAPY USING MULTIDOMAIN BIOTAGS - In one embodiment, a biotag for targeting a cancer biomarker is provided. The biotag may include a cancer biomarker binding domain, an internalization domain, an endosomal escape domain, a lysosomal escape domain, a reporter binding domain, and a reporter, wherein the reporter is a diagnostic agent. In some aspects, the cancer biomarker is ERBB 1-4, EGFRvIII or Transferrin Receptor (TfR). In other aspects, the binding domain is an scFv, an sdFv, a CDR or an SDR modified CDR. In some aspects, the reporter binding domain is a metal binding domain, which may be chelated to a metal nanoparticle tag. In some aspects, the metal nanoparticle tag is a noble metal, a superparamagnetic metal, a core-shell nanoparticle, or a fluorescent agent. In another embodiment, a targeted contrast composition for use with a diagnostic imaging technique is provided, which includes a contrast agent and a biotag for targeting a cancer biomarker. | 04-05-2012 |
20120083006 | METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS - The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or for the purification or identification of kinase proteins. | 04-05-2012 |
20120094311 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 04-19-2012 |
20120100560 | DEVICE FOR CAPTURE, ENUMERATION, AND PROFILING OF CIRCULATING TUMOR CELLS - Applications in nanomedicine, such as diagnostics and targeted therapeutics, rely on the detection and targeting of membrane biomarkers. The present invention, in one embodiment, utilizes quantitative profiling, spatial mapping, and multiplexing of cancer biomarkers using functionalized quantum dots. This approach provides highly selective targeting molecular markers for pancreatic cancer with extremely low levels of non-specific binding and provides quantitative spatial information of biomarker distribution on a single cell, which is important since tumors cell populations are inherently heterogeneous. The quantitative measurements (number of molecules per square micron) is validated using flow cytometry and demonstrated using multiplexed quantitative profiling using color-coded quantum dots. | 04-26-2012 |
20120100561 | A PKN3/RHOC MACROMOLECULAR COMPLEX AND METHODS OF USE THEREFOR - Disclosed are compositions comprising and methods of using a novel macromolecular assembly comprising PKN3, PDK1 and RhoC (PPRC complex). The PPRC complex was shown to have kinase activity and was found in cells of high malignancy potential, such as particularly aggressive cancers. In some aspects, the invention provides methods for screening compounds that have cancer therapeutic potential, methods for diagnosing aggressive cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial or determining the effectiveness of a particular treatment regimen, polypeptides that modulate the formation of the PPRC complex, and kits comprising one or more components of the PPRC complex. | 04-26-2012 |
20120107837 | METHOD FOR SCREENING ANTICANCER SUBSTANCES, SET OR KIT FOR IMPLEMENTING SAID METHOD - A method for screening anticancer substances including the following steps:
| 05-03-2012 |
20120107838 | Cancer Diagnostics - The invention concerns kits and methods for the diagnosis, prognosis and monitoring of cancer. In one aspect, there is provided a method for identifying whether or not a mammal is suffering from cancer, wherein the method comprises the steps of: (a) measuring a signal due to a non-IgG immunoglobulin binding to a carbohydrate-containing antigen in a sample from the mammal; and (b) comparing the signal measured in step (a) with a signal due to the non-IgG immunoglobulin binding to the carbohydrate-containing antigen in one or more samples from one or more mammals known to have cancer and/or with a signal due to the non-IgG immunoglobulin binding to the carbohydrate-containing antigen in one or more samples from one or more healthy mammals. | 05-03-2012 |
20120107839 | NMR DEVICE FOR DETECTION OF ANALYTES - This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient. | 05-03-2012 |
20120115167 | METHOD AND APPARATUS FOR ISOLATING A TARGET BIOENTITY FROM A BIOLOGICAL SAMPLE - A method for isolating a target bioentity from a biological sample, comprises contacting the biological sample with a magnetically-labelled ligand having selective binding affinity for the target bioentity, or for a determinant on the target bioentity, to form a target bioentity/labelled ligand complex, locating a separation module having a defined fluid flow path in the magnetic field of a magnetic module, the magnetic module comprising an array of at least two magnets in which adjacent magnets in the array are aligned with opposing polarity; passing the biological sample through the separation module to subject the biological sample to the magnetic field while the sample is passing through the defined fluid flow path to magnetically capture the target bioentity/labelled ligand complex by arresting or hindering movement of the complex within the defined fluid flow path; removing the separation module from the magnetic field; and recovering the target bioentity/labelled ligand complex from the fluid flow path. | 05-10-2012 |
20120122120 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor. | 05-17-2012 |
20120122121 | ANTIBODIES AND IMMUNOTOXINS THAT TARGET HUMAN GLYCOPROTEIN NMB - The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. | 05-17-2012 |
20120129190 | ENSEMBLE-DECISION ALIQUOT RANKING - Provided herein, among other aspects, are methods and apparatuses for ranking aliquots from a suspension containing bioparticles. In certain embodiments, the bioparticles may be cells, organelles, proteins, DNAs, debris of biological origin, microbeads coated with biological compounds, or viral particles. As such, the methods and apparatuses provided herein may be used to quantify rare cells such as circulating cancer cells, fetal cells and other rare cells present in bodily fluids for disease diagnosis, prognosis, or treatment. | 05-24-2012 |
20120129191 | COCKTAIL ANTIBODY, DETERMINATION KIT AND DETERMINATION METHOD FOR DETERMINING HISTOLOGICAL TYPE OF CARCINOMA - The present invention provides a cocktail antibody useful for determining the histological type of cancer, and a determination method using the same cocktail antibody is disclosed. A determination kit is also provided. | 05-24-2012 |
20120129192 | Apparatus and Methods for Detection of Tumor Cells in Blood - In one embodiment, the present invention provides the description of an inexpensive and disposable handheld device for detecting Circulating tumor cells (CTC) in blood called a handheld CTC detector (HCTCD). The HCTCD is capable of detecting less than | 05-24-2012 |
20120135424 | MER DIAGNOSTIC AND THERAPEUTIC AGENTS - Mer diagnostic and therapeutic agents are disclosed. The agents are useful in the diagnosis and treatment of a variety of diseases including leukemia, lymphoma, and clotting disorders. | 05-31-2012 |
20120142030 | Biomarkers for Follicular Thyroid Carcinoma and Methods of Use - The present invention provides protein biomarkers for determining whether a thyroid nodule is malignant or benign and methods for using the same. | 06-07-2012 |
20120156698 | Device and Methods for the Detection of Cervical Disease - The present invention discloses a novel device and methods thereof with utility application in the high-throughput detection, screening and disease management of cervical disease. The “multiwell” device of the present invention consists of a solid support featuring multiple well-separated areas, each accommodating a patient sample, leading to simultaneous evaluation of patient samples. The methods of the present invention comprise conventional cytological staining, cervical Pap staining, and immunochemical staining using antibodies or combination of antibodies which are capable of binding to biomarkers that are overexpressed in cancer including in cervical carcinoma and dysplasia, as compared to normal controls. The device and methods of the present invention can be practiced in either manual or automated mode, and applied to any biological fluid or cell suspension from any biological specimen in view of a variety of cell biology assays, and in view of detection and screening of cervical and other diseases. | 06-21-2012 |
20120171700 | CELL IDENTIFYING APPARATUS AND CELL IDENTIFYING METHOD - A cell identifying apparatus includes a capillary through which a sample flow passes, an irradiating unit that irradiates irradiation light, a light receiving unit that receives transmitted light and outputs a transmitted light signal based on the transmitted light, a measuring unit that receives the transmitted light signal output from the light receiving unit and measures the change of the transmitted light signal caused by cells, an identifying unit that identifies whether the cells are peripheral blood cells on the basis of a value of an extreme point in the change of the transmitted light signal, the change being caused by the cells and measured by the measuring unit, a sorting unit that sorts the cells in a predetermined vessel, on the basis of the identification result of the identifying unit, and a supplying unit that supplies the sample flow to the capillary. | 07-05-2012 |
20120178104 | Spatial Biomarker of Disease and Detection of Spatial Organization of Cellular Receptors - A signature of a condition of a live cell is established in an assay that allows distribution of the receptors on the cell surface in response to binding a ligand. The receptors can be optically detected and quantified to provide a value for the condition, Test drugs can be screened for therapeutic potential in the assay: a potentially efficacious drug is identified by an ability to modulate an established signature. The receptor distribution signature can be corroborated with an mRNA expression profile of several genes, indicating, for example, metastasis. | 07-12-2012 |
20120190049 | GLYPICAN-3 TARGETING OF LIVER CANCER CELLS USING MULTIFUNCTIONAL NANOPARTICLES - Method for labeling and detecting liver cancer cells using an anti-glycipan-3 antibody as a targeting agent and a magnetic nanoparticle as an imaging agent. | 07-26-2012 |
20120214174 | GENE AND POLYPEPTIDE RELATING TO BREAST CANCER - Herein disclosed are methods of identifying substances suitable for the treatment and prevention of cancer, particularly cancers associated with the overexpression of GALNT6 gene. Methods of the present invention use or target the binding between GALNT6 protein and MUC1 protein, and the glycosylation of MUC1 protein by GALNT6 protein as an index of cancer, particularly breast cancer. | 08-23-2012 |
20120225439 | PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer. | 09-06-2012 |
20120231478 | TIVOZANIB RESPONSE PREDICTION - A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry. | 09-13-2012 |
20120237952 | MYOSIN-IIA S1943 PHOSPHORYLATION AS A MARKER OF TUMOR INVASION - Methods and kits are provided for determining if cells of a tumor in an organ or a tissue in a subject are likely to invade another organ or tissue in the subject and for determining if a cancer in a subject is likely to metastasize. | 09-20-2012 |
20120237953 | Methods to Identify Modulators - Sucralose-binding TAS2R bitter taste receptors have been identified. Novel methods to identify modulators and in particular inhibitors to the bitter taste of sucralose, and an inhibitor, are provided. | 09-20-2012 |
20120244556 | MARKERS FOR IDENTIFYING TUMOR CELLS, METHODS AND KIT THEREOF - The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction. | 09-27-2012 |
20120252038 | STEROID RECEPTOR ASSAYS - Methods for the detection, enumeration and analysis of circulating tumor cells expressing steroid receptors, particularly estrogen receptors are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided. | 10-04-2012 |
20120258475 | RECOVERY OF RARE CELLS USING A MICROCHANNEL APPARATUS WITH PATTERNED POSTS - A microflow apparatus for separating or isolating cells from a bodily fluid or other liquid sample uses a flow path where straight-line flow is interrupted by a pattern of transverse posts. The posts are spaced across the width of a collection region in the flow path, extending between the upper and lower surfaces thereof; they have rectilinear surfaces, have arcuate cross-sections, and are randomly arranged so as to disrupt streamlined flow. Sequestering agents, such as Abs, are attached to all surfaces in the collection region via a hydrophilic coating, preferably a hydrogel containing isocyanate moieties or a PEG or polyglycine of substantial length, and are highly effective in capturing cells or other targeted biomolecules as a result of such streamlined flow disruption. | 10-11-2012 |
20120264140 | METHODS AND KITS TO DETECT AND MONITOR OVARIAN CANCER AND PREECLAMPSIA - The present invention provides methods and kits related to a prognostic, and, in certain embodiments, diagnostic indicator for ovarian cancer which comprises measuring the level of MUC16 bound to immune cells. The level of MUC16 bound to immune cells can by itself be an indicator of disease regression or recurrence, or this indicator can be used in conjunction with assays for serum CA125 and other diagnostic markers. The invention further provides methods and kits related to the detection of ovarian cancer by measuring levels of Siglec-9 expression on immune cells. As well, related methodologies are provided for the detection of preeclampsia in pregnant human subjects. | 10-18-2012 |
20120270237 | METHODS FOR THE IDENTIFICATION OF KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF KINASE PROTEINS - The present invention relates to immobilization compounds (I), immobilization products and preparations thereof as well as methods and uses for the identification of kinase interacting compounds or for the purification or identification of kinase proteins. | 10-25-2012 |
20120270238 | Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof - The present invention provides an active binding sequence of mammalian alpha-fetoprotein (AFP) to the receptor of AFP (AFPr or RECAP). The sequence is embodied in peptides comprising Lys-Glx-Glx-Xaa-Leu-Ile-Asn (SEQ. ID. NO: 1) and variants thereof, wherein GIx means GIn or GIu, each GIx being selected independently of the other, and Xaa represents Phe or Leu. The peptides bind a site of the AFP receptor. This peptide can be used as a substitute for AFP in the detection, purification and imagining of RECAF. This peptide, as it binds to RECAF which is elevated in cancer cells, allows for a method of diagnostic determination of cancer or chemotherapeutic delivery using cytotoxic or radiological agents. | 10-25-2012 |
20120270239 | MELANOMA PROGNOSTIC MODEL USING TISSUE MICROARRAYS AND GENETIC ALGORITHMS - The invention provides a method for determining the risk that a patient diagnosed with melanoma will develop a recurrence of melanoma comprising: a) determining the level of expression for each marker of a panel of markers, wherein the panel comprises activating transcription factor 2, p21 | 10-25-2012 |
20120276555 | Method of Using Non-Rare Cells to Detect Rare Cells - The invention provides seminal computational approaches utilizing data from non-rare cells to detect rare cells, such as circulating tumor cells (CTCs). The invention is applicable at two distinct stages of CTC detection; the first being to make decisions about data collection parameters and the second being to make decisions during data reduction and analysis. Additionally, the invention utilizes both one and multi-dimensional parameterized data in a decision making process. | 11-01-2012 |
20120282631 | METHOD FOR DIAGNOSIS NON-SMALL-CELL-LUNG-CARCINOMA (NSCLC) AND CLASSIFICATION OF ITS SUBTYPES WITH DIFFERENT COMBINATIONS OF 6 PROTEIN BIOMARKERS - A method of identifying and classifying non-small-cell lung carcinoma in a biological sample includes a first test wherein the expression level of at least one biomarker is measured in a sample, the at least one=biomarker is selected from a first group consisting of chaperonin, 2,3-bisphosphoglycerate mutase, thymidine phosphorylase, and minichromosome maintenance deficient protein 5, and comparing the measured expression levels against a normal expression level, wherein a significant difference diagnoses or aids in the diagnosis of non-small cell lung carcinoma; and a second test wherein the expression level of at least one biomarker is measured in the sample, the at least one biomarker is selected from a second group consisting of selenium binding protein and Napsin A, and comparing the measured expression level against a normal expression level, wherein a significant difference confirms or aids in confirmation of Non-Small Cell Carcinoma. | 11-08-2012 |
20120282632 | FUNCTIONALIZED CHROMOPHORIC POLYMER DOTS AND BIOCONJUGATES THEREOF - The present invention provides, among other aspects, functionalized chromophoric polymer dots comprising a hydrophobic core and a hydrophilic cap, and bioconjugates thereof. Also provided are improved methods for preparing functionalized chromophoric polymer dots. Methods for in vivo imaging and molecular labeling are also disclosed. | 11-08-2012 |
20120282633 | ANTIBODY SPECIFIC TO ACTIVATED EGFR - Disclosed is a means for accurately measuring activated EGFR regardless of whether phosphorylation has occurred or not. The antibody or antigen-binding fragment thereof according to the present invention can bind to activated EGFR regardless of whether the activated EGFR is in a phosphorylated form or in a nonphosphorylated form. By carrying out an immunoassay using the antibody or antigen-binding fragment thereof, activated EGFR in a sample can be measured more accurately than by conventional methods. Abnormal activation of EGFR is responsible for the onset of cancer, and is regarded as a therapeutic target. Therefore, the antibody or antigen-binding fragment thereof according to the present invention is also useful for detection of cancers, in particular, cancers to which a molecular target drug(s) whose target is EGFR is(are) to be administered. | 11-08-2012 |
20120288876 | NOVEL IDENTIFIED ONCOGENE WITH KINASE-DOMAIN (NOK) - A newly identified oncogene with kinase domain (NOK) and its encoded polypeptide, and vectors, fusions, host cells and transgenic animals comprising the said nucleotide sequence. Furthermore, the present invention also describes the methods for diagnosing diseases including tumor and the methods for screening agents capable of inhibiting the occurrence and/or metastasis of tumor. | 11-15-2012 |
20120288877 | ELECTROCHEMICAL METHODS OF DETECTING COLON CANCER CELLS AND USE OF SAME FOR DIAGNOSING AND MONITORING TREATMENT OF THE DISEASE - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with the substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of the electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy. | 11-15-2012 |
20120295284 | Fluorecent Saccharide Conjugates - The present invention relates to improved fluorescently labeled monosaccharide and low molecular weight oligosaccharide conjugates for immunofluorescent staining, confocal microscopic imaging and flow cytometry/fluorescence activated cell sorting (FACS). These fluorophore conjugates target cells, components of cell surfaces and extracellular components; and are useful as probes for tumor targeting and cellular uptake. | 11-22-2012 |
20120301900 | APPARATUS AND METHOD FOR DETECTING TUMOR CELLS - Provided are an apparatus for detecting tumor cells including a tumor cell detection chip and a method for detecting tumor cells. The apparatus and method for detecting tumor cells according to the present disclosure enable convenient detection of tumor cells in short time and thus allow for treatment prior to metastasis of the tumor cells as well as easy diagnosis and clinical management of cancer patients. In addition, the detected tumor cells may be cultured as they are for use in genetic analysis. | 11-29-2012 |
20120309029 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells. | 12-06-2012 |
20120329076 | Antibodies to Non-Functional Oligomeric P2X7 Receptors - The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to use of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X7 receptors expressed by live cells. | 12-27-2012 |
20130004970 | METHODS FOR PREDICTION OF CLINICAL OUTCOME TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS BY CANCER PATIENTS - Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors. The invention provides a diagnostic paradigm based on each of these tests and combinations of these tests to select cancer patients who will benefit from EGFR inhibitor therapy, as well as a diagnostic paradigm to select cancer patients who will not benefit from EGFR inhibitor therapy. | 01-03-2013 |
20130022995 | METAL NANOWIRE INCLUDING GOLD NANOCLUSTERS ON A SURFACE THEREOF FOR BINDING TARGET MATERIAL AND METHOD OF BINDING THE TARGET MATERIAL TO THE METAL NANOWIRE - A metal nanowire including gold nanoclusters on the surface thereof for binding a target material and a method of binding the target material to the metal nanowire are provided. | 01-24-2013 |
20130029354 | MULTIPLE SEPARATION DEVICE AND METHOD FOR SEPARATING CANCER CELLS IN BLOOD USING THE DEVICE - Provided are a multiple separation device and a method of separating cancer cells in blood using the device. In this device and method, twice magnetophoresis separation steps are performed. At a second magnetophoresis separation step, shapes of ferromagnetic patterns are changed to separate cancer cells into cancer kinds. | 01-31-2013 |
20130029355 | MULTIPLE ANALYSIS DEVICE AND METHOD FOR ANALYZING CANCER CELLS IN BLOOD - Provided are a multiple analysis device and a method of analyzing cancer cells in blood using the device. In this device and method, it can analyze the cancer cells along cancer kinds by using the magnetic nanoparticles combined to the markers of the cancer cells and the difference of the magnetic fields of them. | 01-31-2013 |
20130029356 | METHODS AND SYSTEMS FOR USING DRUGS AS BIOMARKERS - Methods and systems for using drugs as biomarkers to investigate the status of biological systems are disclosed. A drug is conjugated with a light emitting dye that emits light in a channel of the electromagnetic spectrum when an appropriate stimulus is applied. In one aspect, a suspension suspected of containing target particles is added to a tube along with the conjugated drug/dye complex and a float. Centrifugation of the tube, float, and suspension causes various components to separate along the axial length of the tube. Binding of the drug/dye complex to the target particles can be assessed by applying an appropriate stimulus to the tube, which, in turn, causes the fluorescent dyes to emit light in the channel. The level of fluorescence of the target particles located between the float and the inner wall of the tube can be used to assess use of the drug in therapy. | 01-31-2013 |
20130029357 | DIAGNOSTIC MARKER FOR EFFECT OF ANTICANCER AGENT - The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer. | 01-31-2013 |
20130045490 | ANTIBODY AGAINST MUCIN 1 (MUC1) PROTEIN AND USE OF SAME - The present invention provides means and a method assuring the effectiveness of early diagnosis of cancers including gastric cancers. Specifically, the present invention provides an antibody, which is prepared using, as an antigen, (a) a peptide comprising at least contiguous amino acids at positions 69 to 75 in the amino acid sequence of SEQ ID NO: 2, or (b) a peptide consisting of an amino acid sequence in which one or several amino acids are deleted, substituted or added in at least contiguous amino acids at positions 69 to 75 in the amino acid sequence of SEQ ID NO: 2, and having the antigenicity of human MUC1 protein, and which is reactive with human mucin 1 (MUC1) protein. | 02-21-2013 |
20130052664 | METHOD AND KIT FOR ISOLATING TARGET CELL - Provided are a method and kit for isolating a target cell by using particles comprising polymers having positive charge and negative charge and at least one antibody bound to polymers. The target cell in the biological sample may be efficiently isolated and detected by using a method and kit according to an exemplary embodiment. | 02-28-2013 |
20130071859 | Methods of Determining Patient Response by Measurement of HER-3 - The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3. | 03-21-2013 |
20130078650 | IDENTIFYING MATERIAL FROM A BREAST DUCT - Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided. | 03-28-2013 |
20130089872 | ANTI-HUMAN TROP-2 ANTIBODY HAVING ANTI-TUMOR ACTIVITY IN VIVO - The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor. | 04-11-2013 |
20130089873 | MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 04-11-2013 |
20130102011 | HUMAN LEUCINE-RICH A-2-GLYCOPROTEIN-1 AND AMINOPEPTIDASE N AS RISK INDICATORS FOR CANCER - Diagnostic tests for characterizing a test subject's risk of developing or having cancer, based on determining the level of LRG1 and/or CD13 in a bodily sample obtained from a test subject are described. Levels of LRG1 and/or CD13 are then compared to a predetermined value that is derived from measurements of the levels of LRG1 and/or CD13 in comparable bodily samples obtained from control subjects. Such comparison characterizes the test subject's risk of developing or having cancer. | 04-25-2013 |
20130115628 | METHOD FOR SELECTION OF CHEMOTHERAPEUTIC AGENTS FOR ADENOCARCINOMA CANCER - The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy. | 05-09-2013 |
20130115629 | METHODS OF BREAST CANCER DETECTION - Methods of diagnosing breast cancers are provided. The methods include analyzing the expression patterns of biomarkers in a plurality of cells to distinguish between invasive and non-invasive cancers, usual and atypical hyperplasias, and basal-like breast cancers. Breast cancers are diagnosed based upon different combinations of the biomarkers found in nipple aspirate fluid. | 05-09-2013 |
20130130279 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 05-23-2013 |
20130143236 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO DASATINIB AND COMPUTER PROGRAM - The present invention provides a method for determining sensitivity of tumor cells to dasatinib by evaluating inhibitory capacity of a predetermined tyrosine kinase inhibitor in a measurement sample which is prepared from a biological sample containing tumor cells and a computer program. | 06-06-2013 |
20130143237 | COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS - The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof. | 06-06-2013 |
20130143238 | PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines. | 06-06-2013 |
20130149718 | METHODS OF DETERMINING CELLULAR CHEMOSENSITIVITY - The present invention provides methods of determining cell sensitivity to a therapeutic agent. | 06-13-2013 |
20130164762 | PROGNOSTIC TEST OF THE PROGRESSION OF A SOLID TUMOUR BY IMAGE ANALYSIS - The present invention relates to a method for the prognosis of the progression of a solid tumour in a patient, which includes at least the following steps: a) making, from a tumour sample, a virtual slide on which a tumour front can be identified; b) quantifying, on said virtual slide made in step a), the density of cells and/or blood vessels present in a continuous area covering the tumour front and extending on either side of the tumour front over a distance of at least 0.5 mm, referred to as the quantification area; and c) deducing, from said quantification, the risks of postoperative relapse and/or the sensitivity to various antitumor treatments and/or the risks of developing metastases in said patient. Preferably, the cells to be quantified are leukocytes, such as T cells, B cells, macrophages, natural killer cells, dendritic cells, or subpopulations of these immune system cells. | 06-27-2013 |
20130171666 | Purinergic (P2X) Receptors in Extra-Cellular Body Fluid - The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to anti-bodies for the diagnosis or condition, especially cancer. | 07-04-2013 |
20130171667 | PHOTONIC CRYSTAL FIBER SENSOR - A method for sensing, a photonic crystal fiber, a method for fabricating a photonic crystal fiber sensor, and a Surface Enhanced Raman Scattering (SERS) sensing apparatus. The method for sensing comprises the steps of providing a photonic crystal fiber comprising a hollow core and a plurality of cladding holes around the hollow core; providing Surface Enhanced Raman Scattering (SERS) active nanoparticles; and adapting the SERS active nanoparticles and/or the fiber for SERS sensing. | 07-04-2013 |
20130177927 | Protein markers for esophageal cancer - Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from esophageal tumors, reveals proteins which are different in tumor and control tissue. | 07-11-2013 |
20130196349 | In Vitro Tumor Metastasis Model - This invention provides a system and methods for modeling tumor metastasis in vitro where primary tumor tissue is cultivated in an orientation and an environment such that the natural composition, three-dimensional organization, and environmental conditions of the tumor can be adjusted. The invention further provides mechanism for inducing tumors to undergo metastatic processes resulting in production of tumor progenitor or stem cells that can be collected, characterized, or used to induce tumors in normal tissue constructs in vitro. | 08-01-2013 |
20130196350 | SENSITIVITY AND SPECIFICITY FOR OVARIAN CANCER - Improved ovarian cancer assays are provided. | 08-01-2013 |
20130196351 | Methods of Evaluating BAFF - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject. | 08-01-2013 |
20130203080 | NEW RECEPTOR BINDING LIGANDS, THEIR USE IN THE DETECTION OF CELLS WITH BIOLOGICAL INTEREST - A method for the identification and quantification of the expression of membrane receptors present on the surface of target cells using at least two soluble receptor binding ligands derived from the soluble part of the glycoprotein of an enveloped virus that interacts with a cellular cognate receptor, the receptor binding ligand containing a part or the totality of one of the receptor binding domains (RBD) of the glycoprotein, and the soluble receptor binding ligand being liable to interact with the at least one membrane receptor of a target cell, for the identification and quantification of the expression of membrane receptors present on the surface of target cells, the identification and quantification taking place at a given time or during a given time interval, and allowing the determination of a physiological state of the target cell. | 08-08-2013 |
20130203081 | TUMOR CELL-DERIVED MICROVESICLES - The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer. | 08-08-2013 |
20130203082 | METHOD FOR DETERMINING CANCER ONSET OR CANCER ONSET RISK - A highly accurate and quantitative method for determining cancer onset or cancer onset risk by a quantitative tissue staining method in biological tissues using an antibody capable of recognizing a cancer growth regulatory factor or cancer metastasis regulatory factor such as PAR1 antibody, which inhibits the cancer cell mobility and infiltration is provided. Cancer onset or cancer onset risk is determined using the tissue staining method comprising the steps of: labeling an antibody which recognizes a cancer growth regulatory factor or cancer metastasis regulatory factor with a fluorescent material, and contacting the fluorescent-labeled antibody with a tissue sample; irradiating a tissue site in contact with the antibody with excitation light to acquire a fluorescence image; acquiring an autofluorescence image in a vicinity region of a short wavelength side or long wavelength side of an acquisition region of fluorescence wavelength emitted by the fluorescent material, in the same field of vision and in the same focal point as those of the fluorescence image; acquiring a corrected fluorescence image by image processing to eliminate a fluorescent brightness of the autofluorescence image from the fluorescent brightness of the fluorescence image; counting the number of cells at the tissue site in contact with the antibody; measuring a mean fluorescent brightness of a single fluorescent particle; and calculating the number of fluorescent particles per cell. | 08-08-2013 |
20130210034 | COMPLEX PHOSPHOPROTEIN ACTIVATION PROFILES - The present specification discloses methods for determining a phosphoprotein activation profile in hematopoietic cells, methods for detecting a signal transduction activation state in an individual having or suspected of having a disease or condition associated with activation of a signal transduction pathway, methods for detecting leukemia, and kits for determining a phosphoprotein activation profile in a sample containing hematopoietic cells. | 08-15-2013 |
20130217037 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS, APPLICATION TO THE HIGH-DENSITY LABELING OF CELL MEMBRANES - The present invention relates to nanoparticles the surface of which is modified by deposition of proteins. The invention further relates to a method for producing said nanoparticles and to their use in biological research and in the biomedical field (for example labelling and diagnosis). | 08-22-2013 |
20130230866 | Method for Determining Effectiveness of Medicine Containing Antibody as Component - Protein recognized by an antibody used as an active ingredient of an antibody medicine such as trastuzumab or an antibody used for targeting a target site of an active ingredient is highly accurately quantitatively determined by employing a quantitative tissue staining method of biological tissues, thereby providing a method for determining therapeutic effectiveness of a medicine containing such an antibody as a component. The effectiveness of a medicine containing an antibody as a component is determined by employing a tissue staining method comprising the steps of: labeling the antibody in the medicine containing an antibody as a component with a fluorescent material and contacting the thus fluorescence-labeled antibody with a tissue sample; obtaining a fluorescence image by irradiating, with excitation light, a tissue site contacted with the antibody; obtaining an autofluorescence image in the same field of view and at the same focus as in the fluorescence image in a close region on a shorter wavelength side or a longer wavelength side of an acquisition wavelength region of fluorescence emitted by the fluorescent material; obtaining a corrected fluorescence image by performing image processing for removing fluorescence brightness of the autofluorescence image from fluorescence brightness of the fluorescence image; counting the number of cells in the tissue site contacted with the antibody; measuring average fluorescence brightness per fluorescent particle; and calculating the number of fluorescent particles per cell. | 09-05-2013 |
20130236912 | Use Of Quinolinone Derivatives As A Research Tool - The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I). | 09-12-2013 |
20130236913 | SEROLOGICAL MARKERS FOR DETECTING COLORECTAL CANCER AND THEIR APPLICATION FOR INHIBITING COLORECTAL CANCER CELLS - Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61β (SEC61β) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61β protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells. | 09-12-2013 |
20130244255 | ANTIBODIES DIRECTED TO GPNMB AND USES THEREOF - The present invention relates to antibodies with specificity to GPNMB, and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides biomarkers for evaluating the effects of therapeutic methods and uses of the antibodies with specificity to GPNMB. | 09-19-2013 |
20130244256 | Compositions and Methods for Treating and Diagnosing Cancer - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells. | 09-19-2013 |
20130252259 | Methods for the Detection of Circulating Tumor Cells - The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers. | 09-26-2013 |
20130260392 | TAGGED LIGANDS FOR ENRICHMENT OF RARE ANALYTES FROM A MIXED SAMPLE - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 10-03-2013 |
20130260393 | TEM-1 DIAGNOSTIC ANTIBODIES - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer, gastric cancer, hepatocellular cancer, or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample. | 10-03-2013 |
20130266965 | Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHA - The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor. | 10-10-2013 |
20130280735 | Gene Expression Control DNA Element and Associated Protein - Through screening of an expression library, a cDNA sequence has been identified that encodes a protein that interacts with human CD33, the DNA being highly homologous to a portion of the human dystrophin gene. A region of that cDNA has been identified as an important regulatory element in controlling expression, both transcription and translation, of the DNA with which it is associated. This DNA sequence element may be used as a regulatory cassette in conjunction with any suitable gene, to modify gene expression. The putative controlling DNA sequence element contains a minimum of 137 base pairs (FIG. | 10-24-2013 |
20130288273 | Method for Detecting Cancer Cell - A method for detecting a cancer cell, including: contacting in vitro a peripheral blood-containing sample including test cells and a labeling substance; allowing the test cells to incorporate the labeling substance to label the test cells; and detecting, as a cancer cell, a cell showing a higher degree of labeling with the labeling substance than that shown by a normal cell in the peripheral blood-containing sample. | 10-31-2013 |
20130302828 | METHOD FOR DETECTING LOW CONCENTRATIONS OF SPECIFIC CELL FROM HIGH CONCENTRATIONS OF CELL POPULATIONS, AND METHOD FOR COLLECTING AND ANALYZING DETECTED CELL - Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable. The identifying and counting step includes evaluating the respective absolute concentrations of live and dead CTCs in a volume of blood by automatically identifying CTCs by the ratio of a plurality of fluorescence signal intensities using a flow cytometer, and differentiating between and counting the live CTCs and the dead CTCs. In the cytometer, an entire liquid-feeding system that includes a flow cell can be replaced for each sample, and the total amount of a liquid sample can be measured. | 11-14-2013 |
20130302829 | METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY - This invention provides methods for determining or predicting response to HER2-directed therapy in an individual. | 11-14-2013 |
20130316374 | BREAST CANCER DIAGNOSTICS - The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient. | 11-28-2013 |
20130323755 | DIAGNOSTIC TUMOR MARKERS, DRUG SCREENING FOR TUMORIGENESIS INHIBITION, AND COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed. | 12-05-2013 |
20130323756 | METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES - Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, composition and kits that utilize lectins to quantify exosomes are provided. | 12-05-2013 |
20130330742 | Assay for colon and other cancers in humans - The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. The novel antigen disclosed is a 60,000 Dalton glycoprotein found on the cell surface of human tumor cells. | 12-12-2013 |
20130337471 | CELL IDENTIFICATION WITH NANOPARTICLES, COMPOSITIONS AND METHODS RELATED THERETO - The present disclosure provides a method for identifying rare or low-abundant biological entities such as Hodgkin's and Reed-Sternberg cells, circulating tumor cells in peripheral blood, circulating fetal cells, stem cells, somatic cells, HIV-infected T cells, bacteria or viruses in water, adenoviruses, enteroviruses, hepatitis A and E, dengue, Swine Flu, bovine diarrhea, and protozpa/helminthes. The method uses a suite of nanoparticle-conjugated agents to mark biological targets of interest for subsequent fluorescence imaging. In certain embodiments, the nanoparticle-conjugated agents are fluorescent semiconductor nanocrystals conjugated with antibodies with affinity for CD15, CD30, CD45, and Pax5. In certain embodiments, a method is developed to differentiate Hodgkin's and Reed-Sternberg (HRS) cells from amongst surrounding immune cells such as T and B lymphocytes with greater specificity and precision than traditional immunohistochemistry (IHC) for the diagnosis of Hodgkin's lymphoma. | 12-19-2013 |
20130337472 | CELL DIVISION MARKER - This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age. | 12-19-2013 |
20130337473 | CELL IDENTIFICATION SYSTEMS AND METHODS USING FUNCTIONALIZED MICROPALLET ARRAYS - Cell identification systems and methods using micropallet arrays are disclosed. According to one embodiment, a cell identification strategy involves detecting the expression patterns of markers that are expressed on cells to uniquely identify different cell populations within heterogeneous mixtures of cells. The cell markers may be on the cell surface or intracellular in location. The cell markers are interrogated using monoclonal antibodies (mAbs) that are directly conjugated to flourophores. The mAb-flourophore conjugates are used to detect the presence or absence and relative level of expression of each of the cell markers using laser scanning confocal microscopy. | 12-19-2013 |
20130337474 | DETECTION OF ACUTE MYELOID LEUKAEMIA - The present invention relates to diagnostic screens, antibodies, methods and kits for detection/prognosis of acute myeloid leukaemia. The diagnostic screen detects the presence (+) or absence (−) of the cell surface polypeptide markers i) CD34+; ii) CD45RA+; and iii) CD90− and/or CD123+. Antibodies specific for one or more of said cell surface polypeptide markers may be used in the diagnostic screen of the invention. Diagnostic and prognostic methods for detecting and monitoring minimal residual disease based on said screen also form part of the invention. | 12-19-2013 |
20130344509 | ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO - The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor. | 12-26-2013 |
20130344510 | IDENTIFICATION OF CANCER PATIENTS LIKELY TO BENEFIT FROM RADIATION THERAPY - Disclosed herein are methods of identifying suitable patients for postoperative radiotherapy based on the discovery that the quantification of ER, beyond simple positive/negative characterization, can provide valuable predictive information for the treatment of cancer, specifically breast cancer, and more particularly may predict a group more likely to respond to RT and spare patients from a potentially harmful treatment. Furthermore, the true quantification of ER expression provides a continuous recurrence risk assessment for patients being treated with tamoxifen, and therefore the standardization of the data across sites and imaging platforms significantly reduces the misclassification of patients when compared to the current standard by which ER expression is determined. | 12-26-2013 |
20140004536 | METHOD FOR DETECTING CELLULAR DNA DAMAGE AND ANTIBODY AGAINST CELL SURFACE ANTIGEN RESPONSIVE TO DNA STRAND BREAKS | 01-02-2014 |
20140011214 | DETECTION OF BIOPOLYMER INTERACTIONS, CANCER CELLS, AND PATHOGENS USING SPLIT-SUPERCHARGED GFP - Systems and methods for detecting protein-protein interactions and/or detecting a targeted cell using a split supercharged protein reporter system are described. | 01-09-2014 |
20140011215 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 01-09-2014 |
20140024047 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF - The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging. | 01-23-2014 |
20140024048 | PROTEIN - The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development. | 01-23-2014 |
20140024049 | Micro-Fluidic System Using Micro-Apertures for High Throughput Detection of Cells - A microfluidic detection system for micrometer-sized entities, such as biological cells, includes a detector component incorporating a plate with a plurality of opening, the plate separating two chambers, one in communication with a fluid source containing target cells bound to magnetic beads. The openings are sized to always permit passage of the magnetic beads therethrough into a lower one of the chambers and are further sized to always prevent passage of the target cells from the upper one of the chambers. The detector component further includes a magnet positioned to pull unbound magnetic beads through the openings and to capture target cells bound to magnetic beads on the surface of the plate. The microfluidic detection system includes a pump flowing the fluid through the detector component at high flow rates of milliliters per minute for high throughput detection of target cells. | 01-23-2014 |
20140030736 | PEPTIDE APTAMERS AGAINST TENASCIN C - The present invention relates to an anti-tenascin C peptide aptamer having a specific amino acid sequence and a diagnosis kit comprising it. The anti-tenascin C peptide aptamer of the instant invention shows a predominant clearance rate due to its small molecular weight as well as specific binding affinity to tenascin C, having excellent advantages in in vivo or ex vivo tumor imaging. | 01-30-2014 |
20140057288 | NOVEL ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE DETECTION AND DIAGNOSIS OF DISEASE - The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis. | 02-27-2014 |
20140057289 | Micro-Fluidic System Using Micro-Apertures for High Throughput Detection of Cells - A microfluidic detection system for micrometer-sized entities, such as biological cells, includes a detector component incorporating a plate with a plurality of opening, the plate separating two chambers, one in communication with a fluid source containing target entities bound to magnetic beads. The openings are sized to always permit passage of the magnetic beads therethrough into a lower one of the chambers and are further sized to always prevent passage of the target entities from the upper one of the chambers. The detector component further includes a magnet positioned to pull unbound magnetic beads through the openings and to capture target entities bound to magnetic beads on the surface of the plate. In a further feature, the microfluidic detection system is configured to pass target molecules through the plate to be bound to a functionalized surface of the lower chamber. | 02-27-2014 |
20140093889 | ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 04-03-2014 |
20140093890 | QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS - The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy. | 04-03-2014 |
20140099653 | DUAL-TARGET BIOSENSOR CELL ASSAYS - A method and apparatus, as defined herein, for use in compound screening, compound profiling, or both assays, for example, against two different cellular targets in, for example, a single cell-type. | 04-10-2014 |
20140106375 | Secreted Tumor-Associated Cytochrome as a Blood-Based Biomarker for Cancer - Disclosed herein are methods for detecting Pgrmc1 in bodily fluids, e.g., blood, plasma and serum, wherein detection of Pgrmc1 is a biomarker for the presence of cancer, e.g., lung cancer or head or neck cancer. Pgrmc1 levels in bodily fluids may be used to predict patient prognosis, e.g., survival and response to therapy. | 04-17-2014 |
20140106376 | METHOD FOR DIAGNOSING GLIOMA AND SCREENING FOR THE THERAPEUTICS OF GLIOMA THROUGH IDENTIFYING PROTEIN RELOCATION - The present invention relates to a method for diagnosing glioma by comparing the protein location of an individual to be diagnosed with the normal control nerve cells. More particularly, the present invention relates to a method for diagnosing glioma including determining that an individual has glioma when the expression level of GFRα4 in the endoplasmic reticulum is higher than that in the plasma membrane, and a method for screening a therapeutic agent for glioma. In the diagnostic method of the present invention, the protein expression levels in particular subcellular locations are compared, thereby accurately diagnosing glioma, diagnosing progression of glioma, and predicting prognosis after glioma surgery. | 04-17-2014 |
20140106377 | BIOMARKER FOR BREAST CANCER - A method for the diagnosis of breast cancer using an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, expresses LAT1 at a significantly high level, as compared to intraductal breast papilloma, which is benign. An anti-LAT1 monoclonal antibody is useful for the discrimination between these two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas, which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer. Therefore, LAT1 can be used as a novel molecular targeting marker for the triple negative breast cancer. | 04-17-2014 |
20140120554 | ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME - A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same. | 05-01-2014 |
20140120555 | ANTI-CXCR4 ANTIBODY WITH EFFECTOR FUNCTIONS AND ITS USE FOR THE TREATMENT OF CANCER - The present application relates to a method of treating cancer by administering an anti-CXCR4 monoclonal antibody capable of inducing effector function(s). | 05-01-2014 |
20140134645 | METHOD OF ISOLATING OR COUNTING TARGET CELLS BY USING PHOTOCLEAVABLE LINKER COUPLED WITH FLUORESCENT DYE - A method of isolating or counting target cells using photocleavable linkers coupled with fluorescent dyes, for qualitative or quantitative analysis of protein, gene analysis, and/or morphological analysis after removing the dye. | 05-15-2014 |
20140134646 | VITRO CAPTURE AND ANALYSIS OF CIRCULATING TUMOR CELLS - This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed. | 05-15-2014 |
20140141454 | MONOCLONAL ANTIBODY TO HUMAN EPITHELIAL CELL ADHESION MOLECULE AND METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING THE SAME - An anti-EpCAM monoclonal antibody is provided which specifically recognizes an epitope different from the epitope which conventionally known anti-EpCAM monoclonal antibodies recognize (the N-terminal EGF-like domain). Also provided is a hybridoma which is capable of producing such monoclonal antibody, and a method for detecting CTC using such monoclonal antibody and a kit for detecting CTC, which is used for the method. The present application provides a monoclonal antibody to the human epithelial cell adhesion molecule (EpCAM) as a solution for the above problem, wherein the monoclonal antibody to the human epithelial cell adhesion molecule (EpCAM) specifically reacts with the CP region of the human epithelial cell adhesion molecule (EpCAM) and is produced by a hybridoma with accession No. NITE BP-1449. There are also provided a method for detecting circulating tumor cells using the above antibody and a kit for detecting circulating tumor cells, which is used for the method, and a hybridoma with accession No. NITE BP-1449. | 05-22-2014 |
20140147861 | MARKERS TO IDENTIFY PRIMARY CELLS FROM TUMOR BIOPSIES - A process that utilizes a panel of primary monoclonal antibodies (mAbs) specific for cell markers that are directly conjugated to fluorophores (Alexa Fluor dyes and Quantum Dots). The mAb-fluorophore conjugates are used to interrogate the presence or absence and relative level of expression of each of the cell markers using laser scanning confocal microscopy. Complex tissues contain various cellular subsets each of which contribute in different ways to the biological behavior and each of which has, if selected well, a unique pattern of cell marker molecules capable of being identified by monoclonal antibodies and therefore provide a specific phenotype. The cell markers may be cell surface or intracellular in location. The expression patterns of heterogeneous mixtures of cells are detected by the mAb-fluorophore conjugates, and are used to decipher the identity of the cells based on their expression or lack thereof, of the cell markers. | 05-29-2014 |
20140147862 | MICROFLUIDIC APPARATUS AND METHOD OF ENRICHING TARGET CELLS BY USING THE SAME - A microfluidic apparatus capable of being mounted on a rotation driving unit. When mounted on the rotation driving unit and rotated, a fluid flow is induced in the apparatus due to a centrifugal force. the microfluidic apparatus includes a sample supplying unit that comprises a sample chamber to house a sample and provides a fluid including a target material in which fine beads are bound to a target cell in the sample; a density-gradient separation unit that houses a density gradient material with a lower density than the target material, and receives the fluid from the sample supplying unit to separate the target material from the fluid based on a density difference; a fluid supplying channel connecting the sample supplying unit to the density-gradient separation unit to form a passage of the fluid; and a fluid supplying valve provided to the fluid supplying channel to selectively allow a flow of the fluid. | 05-29-2014 |
20140154702 | Methods For Treating Cancer Using Combination Therapies - Described are methods, uses, and kits for utilizing a targeted ligand conjugate in combination with a thiol inhibitor or a system x | 06-05-2014 |
20140154703 | CIRCULATING TUMOR CELL CAPTURE ON A MICROFLUIDIC CHIP INCORPORATING BOTH AFFINITY AND SIZE - The invention encompasses methods and devices for diagnosing, theranosing, or prognosing a condition in a patient by enriching a sample in rare cells or other particles. The devices can be a microfluidic device comprising an array of obstacles and one or more binding moieties. The devices and methods can allow for enrichment of cells based on size and affinity, recovery of cells or other particles in locations on the microfluidic device, release of cells or other particles from the microfluidic device, flow of sample through the microfluidic device, and retention of rare cells or other particles from a sample obtained from a patient having a condition. | 06-05-2014 |
20140162292 | Reagent For Diagnosing Tumor, Pharmaceutical Composition, And Screening Method - The present invention provides antibodies useful for diagnosing and treating tumors as well as methods of screening for antitumor agents. More specifically, tumors can be diagnosed and treated using an anti-phosphorylated p62 antibody that recognizes phosphorylation of serine at position 351 of an amino acid sequence of SEQ ID No. 1 or at a position corresponding thereto. An antitumor agent can be obtained by screening for a substance that inhibits the phosphorylation or that dephosphorylates the phosphorylated serine. | 06-12-2014 |
20140170676 | RBM3 in Bladder Cancer - The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group. | 06-19-2014 |
20140170677 | USE OF THE ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCER - The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed. | 06-19-2014 |
20140178900 | ANALYSIS DEVICE AND ANALYSIS METHOD USING THE SAME - Provided are an analysis device and an analysis method. According to the device and the method, a giant magnetoresistance (GMR) sensor unit is formed to be the same as the size of one cancer cell or smaller and magnetic resistance according to the number of magnetic nano particles coupled with the one cancer cell by using the GMR sensor unit, thereby not only diagnosing cancer but also simply and cheaply distinguishing the type of the cancer. | 06-26-2014 |
20140178901 | Molecular Analysis of Tumor Samples - This invention relates to methods for diagnosing cancer, e.g., cancer of epithelial origin, by detecting the presence of tumor cells in a sample, based (at least in some embodiments) on the quantification of levels of four biomarkers, MUC1, EGFR, EpCAM, and HER2. In some embodiments, the methods are performed using diagnostic magnetic resonance (DMR), e.g., with a portable relaxometer or MR imager. | 06-26-2014 |
20140186857 | FLUORESCENT LABEL FOR BIOLOGICAL SUBSTANCE DETECTION METHOD - The present invention provides a fluorescent label that can be used for carrying out a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The fluorescent label is a fluorescent dye-containing nanoparticle in which the parent material is a cross-linked polymer and the fluorescent dye is an aromatic ring-based dye molecule. The cross-linked polymer is suitably a melamine resin or a styrene resin. The aromatic ring-based dye molecule is suitably a perylene and more suitably a perylene diimide. The dye molecule can have a polar group such as sulfonic acid group or its acid halide. | 07-03-2014 |
20140193837 | LUMINESCENT NANOPARTICLE COMPOSITIONS - A composition is disclosed which is capable of being used for detection, comprising a noble metal nanoparticle. The inventive compositions exhibit little interaction with serum proteins while exhibiting pH-dependent adsorption onto live cell membranes. The nanoparticles of the claimed invention are capable of interacting with cell membranes, which in turn permits the advantages of nanoparticle bio-imaging to be extended to many pH dependent biological processes such as targeting acidic tumor microenvironment. | 07-10-2014 |
20140199714 | METHOD FOR DETECTING CANCER CELLS METASTASIZING INTO SENTINEL LYMPH NODE - A method for detecting a sentinel lymph node generating a microenvironment suitable for micrometastasis within the sentinel lymph node of carcinoma cells from a primary tumor or for detecting micrometastasis within the sentinel lymph node. A detecting agent is injected into the primary tumor, or tissue or a lymph node nearby the tumor, which allows the detecting agent to reach the sentinel lymph node by lymphatic circulation. The detecting agent includes colloid particles, an anti-ICAM-1 antibody or an ICAM-1 ligand exposed on an outer surface of the colloid particles, and a detectable label. Positive detection of the detectable label within the lymph vessel or the sentinel lymph node indicates that ICAM-1 is present, and the presence of ICAM-1 indicates that the sentinel lymph node is generating a microenvironment suitable for micrometastasis within the sentinel lymph node of carcinoma cells from the primary tumor or that micrometastasis is occurring within the lymph node. | 07-17-2014 |
20140212895 | Cancer Analysis System - The invention provides for detecting target subpopulations of cells that have high proliferative and renewal properties in animals, including circulating tumor cells, cancer stem cells, hematopoietic stem cells and endothelial progenitor cells. The invention utilizes a defined substrate and media of known property to enrich target cell subpopulations which can be used for future genetic, proteomic and morphological analyses. The method can use image-capture and analysis software to characterize cells based on physical properties, such as size, morphology and kinetic properties. | 07-31-2014 |
20140212896 | METHODS AND COMPOSITIONS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS - All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test. | 07-31-2014 |
20140220597 | NEUREGULIN-1-BASED PROGNOSIS AND THERAPEUTIC STRATIFICATION OF COLORECTAL CANCER - The present invention relates to the prognosis, therapeutic stratification and treatment of colorectal cancer. More in particular, the present invention discloses that significantly increased levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells present in a sample of a patient indicate that the patient has a worse prognosis when compared to patients having low levels of transmembrane type 1 neuregulin-1 in tumor-associated mesenchymal cells. Moreover, the present invention relates to the usage of transmembrane type 1 neuregulin-1 expression in tumor-associated mesenchymal cells to predict resistance to HER1 inhibitors during colorectal cancer therapy and/or to predict whether a patient would benefit from a therapy based on the prevention of neuregulin-1 and/or HER3 activity. | 08-07-2014 |
20140220598 | BIOLOGICAL SUBSTANCE DETECTION METHOD - The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of apart stained for morphological observation when the fluorescent label used for the immunostaining is observed. | 08-07-2014 |
20140234866 | EX VIVO FLOW CYTOMETRY METHOD AND DEVICE - The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula | 08-21-2014 |
20140234867 | Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient. | 08-21-2014 |
20140234868 | USE FOR GLYCOLIPOPROTEIN GINTONIN, ISOLATED AND IDENTIFIED FROM GINSENG, AS A NATURAL MEDICAL-PLANT DERIVED LIGAND - The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on LPA1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation gene) family in G protein-coupled receptors (GPCRs) present in the cell membranes of animals including humans. The gintonin of the present invention can be used to advantage in the prevention and treatment of various diseases arising from reduced calcium concentration and various physiological activities and pharmaceutical activities dependent on calcium, since the gintonin of the present invention interacts with LPA receptors so as to activate a series of signal transmission processes and temporarily induce an increase in free Ca | 08-21-2014 |
20140234869 | Cadherins as Cancer Biomarkers - Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2. | 08-21-2014 |
20140242611 | METHOD FOR DETECTING AND/OR QUANTIFYING AN ANALYTE AT THE SURFACE OF A CELL - The invention relates to a method for quantifying a protein of interest expressed at the surface of a cell or else present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein. | 08-28-2014 |
20140242612 | SYSTEM AND METHOD FOR INTEGRATION OF MOBILE DEVICE IMAGING WITH MICROCHIP ELISA - A system and method for analyzing a biomarker in a biological sample is provided. A biological sample is loaded onto a microchip and an enzyme-linked immunosorbent assay specific to the biomarker is performed on the microchip. A color image of the microchip is generated using a mobile device and a color intensity of a selected portion of the color image is determined. The color intensity is correlated with a biomarker concentration using a baseline curve calculation and the concentration of the biomarker is then reported. | 08-28-2014 |
20140255954 | METHOD OF BREAST CANCER DETECTION - Methods of diagnosing breast cancers are provided. The methods include analyzing the expression patterns of biomarkers in a plurality of cells to distinguish between invasive and non-invasive cancers, usual and atypical hyperplasias, and basal-like breast cancers. Breast cancers are diagnosed based upon different combinations of the biomarkers found in nipple aspirate fluid. | 09-11-2014 |
20140273016 | DEVICE AND METHOD FOR THE DETECTION AND DIAGNOSIS OF AGGRESSIVE AND METASTATIC CANCER AND CANCER STEM CELLS EMPLOYING PODOCALYXIN AND TRA BIOMARKERS - The invention relates to devices and methods to detect podocalyxin and TRA molecules in a biological sample obtained from a patient and therefore, to detect the presence of podocalyxin-expressing and TRA-expressing cancer stem cells in a patient. The invention further relates to devices and methods to determine a diagnosis of aggressive or metastatic cancer by employing podocalyxin and TRA as biomarkers. | 09-18-2014 |
20140273017 | PRO-ANGIOGENIC AND ANTI-ANGIOGENIC HEMATOPOIETIC PROGENITOR CELL POPULATIONS - Methods for identifying active angiogenesis and vasculopathy are described. More particularly, the present disclosure relates to cellular biomarkers, and to methods of screening cellular biomarkers for identifying active angiogenesis. | 09-18-2014 |
20140287436 | Physical Removal Of Biological Agents Detected By A Magnecytometer - A system and method for analyzing a sample of liquid having an NMR signal in response to a magnetic field for the presence of an analyte. Included is an NMR device having a testing section that is adapted to contain a liquid and apply a magnetic field to the liquid. A complex comprised of a conjugate having a field gradient bound to the analyte that is of sufficient magnitude to quench the NMR signal of the liquid, when in the test section whereby the presence of the complex is determined by the absence of the NMR signal. The system and method also include a container having a binding agent therein that has an affinity for the analyte or foreign agent that is used to remove the foreign agent from a patient's blood or plasma. Blood or plasma is shunted through the container to remove or reduce the foreign agent by extracorporeal circulation. | 09-25-2014 |
20140295459 | MARKERS FOR IDENTIFYING TUMOR CELLS, METHODS AND KIT THEREOF - The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction. | 10-02-2014 |
20140295460 | Analyte Detection Using Magnetic Hall Effect - Determining a presence of a target analyte in a fluid sample includes mixing multiple magnetic particles with the fluid sample, in which the magnetic particles are each bound to one or more binding moieties that specifically bind to the target analyte, flowing the fluid sample containing the magnetic particles through a fluidic channel, exposing the fluid sample in the fluidic channel to a magnetic field, measuring a signal from a Hall effect sensor while the fluid sample flows through the fluidic channel, and determining whether the target analyte is present in the fluid sample when the measured signal is in a first range of values. | 10-02-2014 |
20140302529 | FILTERING PARTICLES FROM BLOOD OR OTHER MEDIA - A filter element ( | 10-09-2014 |
20140315220 | CELLULAR RECOGNITION CONJUGATES AND METHODS OF USE FOR THE HISTOLOGICAL ANALYSIS OF CANCER TISSUE USING MALDI-MS IMAGING - Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue. | 10-23-2014 |
20140335541 | B7-H1 AND B7-H4 IN CANCER - Methods of determining prognosis of a subject with cancer or determining risk of cancer progression by assessing expression of B7-H4, or B7-H1 and B7-H4 in combination. | 11-13-2014 |
20140342374 | Acute Leukemia And Lymphoblastic Lymphoma-Specific CD43 Epitope and Use Thereof - The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma. | 11-20-2014 |
20140363826 | DLL3 MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 12-11-2014 |
20140377779 | COMPOSITION FOR DIAGNOSING BREAST CANCER INCLUDING MATERIAL SPECIFICALLY BINDING TO POLYMERIC IMMUNOGLOBULIN RECEPTOR PROTEIN OR FRAGMENT THEREOF, AND METHOD OF DIAGNOSING BREAST CANCER BY USING THE COMPOSITION - A composition for breast cancer diagnosis using a material specifically binding to a polymeric immunoglobulin receptor (PIGR) or a fragment thereof, and a method for detecting breast cancer or acquiring information for breast cancer diagnosis using the composition. | 12-25-2014 |
20140377780 | Vascular Tumor Markers - The present invention relates to a method for identifying neovascular structures in mammalian tissue, wherein said neovascular structures are identified by the detection of at least one specific protein in said tissue. It also relates to a method for identifying diseases or conditions associated with neovascularization, methods for targeting and/or imaging neovascular structures and methods for targeting diseases or conditions associated with neovascularization. Furthermore, the present invention is directed to the use of novel and/or known ligands, preferably antibodies, directed against novel and/or known target proteins for identifying tumor cells in mammalian tissue, preferably mammalian kidney tissue, more preferably mammalian vascular kidney tissue. The present invention also relates to novel ligands, preferably antibodies, fusion proteins comprising said ligands or antibodies, pharmaceutical and diagnostic compositions comprising said ligands, antibodies or fusion proteins, diagnostic and therapeutic methods as well as novel proteins and corresponding polynucleotides, vectors and host cells. | 12-25-2014 |
20140377781 | Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same - Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers. | 12-25-2014 |
20140377782 | SMALL SPECIMEN STAINING AND DIAGNOSING OF CELLS - An immunohistochemical staining of small specimen comprises using a plurality of antibodies and/or antigens to mark certain cells with particular colors of stains in order to distinguish target cells, such as carcinoma cells, in a stained small specimen. For example, antibodies CD44, cytokeratin 20 and p53 may be used for selectively staining a specimen of a urothelial mucosal biopsy on a single slide. Mouse monoclonal antibody CD44 is associated only with reactive urothelial cells, while rabbit monoclonal antibody p53 is associated only with carcinoma cells. Mouse monoclonal antibody cytokeratin 20 is associated with both “umbrella cells” and carcinoma cells, but antibody p53 is not associated with umbrella cells, which are the most superficial urothelial cells and are characterized morphologically from the other cells in a prepared specimen. Thus, diagnosis is facilitated by the staining of carcinoma cells in a contrasting color to normal urothelial cells and superficial urothelial cells. | 12-25-2014 |
20150017660 | METHOD OF EXOSOME ANALYSIS, REAGENT FOR EXOSOME ANALYSIS, AND ANALYZER FOR EXOSOME - The present invention is to provide a method of exosome analysis that can analyze exosome in a sample in a simple manner. | 01-15-2015 |
20150017661 | METHODS FOR DETECTING 5T4-POSITIVE CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF 5T4-POSITIVE CANCER IN A MAMMALIAN SUBJECT - Methods are provided for detecting 5T4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4-positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4-positive metastatic cancer or early stage 5T4-positive cancer. | 01-15-2015 |
20150017662 | METHOD FOR DETECTING AND QUANTIFYING A TARGET PROTEIN OR A TARGET CELL USING AN APTAMER CHIP - The present invention is a method for detecting or quantifying a target cell or a target protein using an aptamer chip, and particularly, in order to detect a target cell, a method for detecting and/or quantifying a target cell by reacting a cell staining solution (e.g. 4′,6-diamidino-2-phenylindole (DAPI)) with an aptamer chip which the target cell is bound, in order to detect a target protein, a method for detecting and/or quantifying a target protein by reacting Coomassie Brilliant Blue solution with an aptamer chip which the target protein is bound, and a method for reusing the aptamer chip, wherein the aptamer chip comprises a board to which the aptamer specifically combining with the target cell or the target protein is bonded by a disulfide bond. | 01-15-2015 |
20150017663 | IDENTIFICATION OF ANTITUMOR COMPOUNDS USING PLACENTA - Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells. | 01-15-2015 |
20150024409 | METHODS AND SYSTEMS FOR PREDICTING DRUG-RESPONSE - Disclosed herein are methods and systems for determining whether a cell is resistant to one or more drugs. Also, disclosed herein are methods and systems for monitoring the treatment of a cancer patient to determine whether the cancerous cells being treated are resistant to the treatment. Further, disclosed herein are methods and systems for predicting the responsiveness of a cell to a drug. Also, disclosed herein are methods and systems to determine the rate of the efficacy of a chemotherapeutic drug on a cancerous, neoplastic or damaged cells | 01-22-2015 |
20150037818 | IRON OXIDE-GOLD CORE-SHELL NANOPARTICLES AND USES THEREOF - Magnetic-optical iron oxide-gold core-shell nanoparticles are disclosed. Methods for making and using the nanoparticles are also disclosed. | 02-05-2015 |
20150044694 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 02-12-2015 |
20150044695 | Method and a Kit To Detect Malignant Tumors and Provide a Prognosis - A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth. | 02-12-2015 |
20150050669 | METHOD AND KIT FOR ISOLATING TARGET CELL - A particle comprising at least one polymer having negative or positive charges and at least one antibody bound to the polymer, wherein the antibody specifically binds to a surface marker of at least one target cell, and kit comprising same. | 02-19-2015 |
20150056635 | Systems and Methods for Anti-PAX8 Antibodies - The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer. | 02-26-2015 |
20150064721 | COMPOSITION AND KIT FOR SEPARATING CANCER CELL, AND METHOD OF SEPARATING CANCER CELL BY USING THE COMPOSITION AND KIT - Provided is a composition and a kit for separating a cancer stem cell or a circulating tumor cell, a method of separating a cancer stem cell or a circulating tumor cell in a biological sample, and a method for diagnosing metastatic cancer. | 03-05-2015 |
20150064722 | METHOD FOR DETECTING THE DEGREE OF MALIGNANCY OF EACH OF THE CIRCULATING TUMOR CELLS, AND A KIT FOR THE SAME - The object of the present invention is to provide an evaluation method capable of accurately determining a metastasis of cancer, the stage of cancer progression, or the malignancy of cancer. | 03-05-2015 |
20150064723 | DUAL MODE SENSOR - A novel dual mode sensor may combine mass-sensing measurements of dynamic-mode cantilevers with electrochemical impedance spectroscopy employed for transduction in sensitive electrochemical biosensors. The integrated design of the sensor may provide simultaneous and continuous measurement of resonant frequency shift and charge transfer resistance of a target analyte bound to a surface of the sensor. Binding of a target analyte to the surface of the sensor may cause charge transfer resistance to increase and the resonant frequency of the sensor to decrease. These simultaneous dynamic modes of the sensor may be utilized to measure an amount of mass of the target analyte accumulated on the surface of the sensor and to reduce and/or eliminate false negative measurement results. | 03-05-2015 |
20150072357 | Cholesteryl Succinyl Silane Bound Proteins and Methods For Producing and Using the Same - The present invention provides a various three-dimensional polymeric scaffold and methods for producing and using the same. In one embodiment, the three-dimensional polymeric scaffold is used to promote cell migration. Yet in another embodiment, the three-dimensional polymeric scaffold comprises enhanced surface functionalization. In one particular embodiment, the polymeric scaffold comprises a plurality of polymer layers, wherein each polymer layer comprises microchannels. Still in another particular embodiment, the composition comprises a fibrous cholesteryl succinyl silane. Yet in another particular embodiment, a polymer comprising cholesteryl succinyl silane attached (e.g., hybridized) to its surface is provided. | 03-12-2015 |
20150079611 | METHOD FOR DETECTING BIOLOGICAL MATERIAL - The present invention provides a staining method in which the fluorescent staining properties in a fluorescently-immunostained specimen are not reduced even when an oil-based mounting medium is used. The present invention also provides a method of preventing deterioration of a fluorescent label caused by irradiation with excitation light and improving the light resistance in a fluorescently-immunostained specimen obtained by the staining method. The biological substance detection method according to the present invention is a biological substance detection method for specifically detecting a biological substance from a pathological specimen, which includes the steps of: immunostaining the specimen with a fluorescent label; immobilizing the thus stained specimen; and mounting the thus immobilized specimen using a mounting medium including an organic solvent not freely miscible with water. In the biological substance detection method, the above-described mounting medium further includes a discoloration inhibitor. | 03-19-2015 |
20150087001 | METHODS FOR PHENOTYPING OF INTACT WHOLE TISSUES - In various embodiments, the present application teaches methods and compositions for tissue clearing in which whole organs and bodies are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches PACT, a protocol for passive tissue clearing and immunostaining of intact organs. In other embodiments, the present application teaches RIMS, a refractive index matching media for imaging thick tissue. In yet other embodiments, the application teaches PARS, a method for whole-body clearing and immunolabeling. | 03-26-2015 |
20150104814 | SAMPLE ANALYSIS METHODS AND APPARATUSES AND DYNAMIC VALVE OPERATION METHODS - Disclosed are sample analysis apparatus and methods. A sample analysis apparatus includes a first unit that rotates a microfluidic apparatus including: a chamber having a space accommodating a sample, a channel that provides a path through which the sample flows; and a valve that selectively opens and closes the channel, a valve driver that supplies energy, used to operate the valve, to the valve in a state of being separated from the microfluidic apparatus, a third unit that rotates the valve driver with respect to a common rotation axis with a rotation axis of the microfluidic apparatus and the third unit, and a control unit that controls the first and third units and the valve driver to supply energy to the valve while the microfluidic apparatus and the valve driver are being rotated at the same rotation speed. | 04-16-2015 |
20150104815 | Porphyrin-Lipid Stabilized Nanoparticles for Surface Enhanced Raman Scattering Based Imaging - Herein are provided nano-particles comprising a nanocore of Raman-scattering material stabilized by a bilayer comprising a porphyrin-phospholipid conjugate, methods of making the same and their use in Surface Enhanced Raman Scattering. | 04-16-2015 |
20150111226 | METHOD FOR PEPTIDE HISTOCHEMICAL DIAGNOSIS - The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients. | 04-23-2015 |
20150111227 | PEPTIDE SPECIFIC FOR OVARIAN CANCER AND APPLICATIONS - The present invention provides a novel peptide with high specificity for recognition of ovarian cancer. The peptide is selected using M13 phage display library and epithelial-enrich-conjugated magnetic beads. Only a small amount of the peptide is required to establish over 80% binding activity to ovarian cancer comparing to low binding activities to other cancers, showing high specificity for ovarian cancer. Thus the peptide of the present invention can be effective in early detection of ovarian cancer. | 04-23-2015 |
20150118694 | METHOD FOR THE DIAGNOSIS OF MAMMALS - A method for assessing if an individual or an animal has a selected condition includes: obtaining a biological sample from the individual or animal; detecting in a time-resolved manner the presence of a disease related target through use of a probe ( | 04-30-2015 |
20150125878 | ANTIBODIES AGAINST CD106 (VCAM-1) - The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof. | 05-07-2015 |
20150125879 | Biodegradable Layer-by-Layer (LbL) Films for Cell Capture and Release - Compositions and methods for providing devices comprised of a substrate and a Layer-By-Layer (LBL) film coated on at least a surface of the substrate, which LBL film comprises binding agents that specifically interact with cells. Such devices are useful, for example, in various cell isolation applications. Among other advantages, such devices permit isolation and release (e.g., via layer degradation) of cells under mild conditions. | 05-07-2015 |
20150132775 | METHOD AND DEVICE FOR DETERMINING CONCENTRATION, CROSSTALK AND DISPLACEMENT FLUORESCENCE CROSS CORRELATION SPECTROSCOPY - The present invention provides a FCCS method for determining the concentration and/or the diffusion coefficient of at least a first labeled species, a second labeled species and/or a complex between said first and second labeled species, in a system, wherein the method comprises the steps of determining a cross-talk parameter K, wherein K is the ratio between the brightness of the first labeled species and the second labeled species at the centre of each focus, as detected for both species in the channel for detecting the second labeled species; using the cross talk parameter K for determining a displacement parameter r | 05-14-2015 |
20150140576 | CANCER SPECIFIC GLYCANS AND USE THEREOF - The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures. | 05-21-2015 |
20150147763 | Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis - The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2. | 05-28-2015 |
20150291929 | HYDROGEL COMPOSITIONS FOR USE IN PROMOTING TUBULOGENESIS - Hydrogel Compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation. In particularly suitable embodiments, the hydrogel compositions of the present disclosure may be used to promote tubulogenesis of endothelial cells. | 10-15-2015 |
20150299664 | Method for the Isolation for Mammalian Stem Cells and Uses Thereof - The present invention concerns the field of stem cell biology, and in particular relates to a method for producing an isolated bona fide population of mammalian stem cells, and uses of the stem cells thus produced. Human glioblastomas (hGBMs) have now been shown to contain a minor subset of cells bearing the defining features of somatic stem cells (SCs) and the ability to establish, expand and perpetuate these tumors. They are defined stem-like tumor propagating cells (TPCs). This has caused a paradigmatic shift in the way we interpret hGBM physiology, for it identifies TPCs as a major culprit to be tackled for the development of novel therapeutics. It also suggests that studying the regulatory mechanisms of normal neurogenesis may point to specific inhibitors of TPCs. | 10-22-2015 |
20150309035 | Antibody Cocktail Systems and Methods for Classification of Histologic Subtypes in Lung Cancer - The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems. | 10-29-2015 |
20150316544 | RELEASABLE MAGNETIC CELL CAPTURE SYSTEM - Compositions and methods for capturing specific cell types from a mixture in a liquid suspension of cells are provided. Targeted magnetic nanoparticles of the invention can be utilized to isolate, quantify, and characterize circulating tumor cells from complex body fluids, such as blood. The magnetic nanoparticles are releasable after targeted cells have been isolated, leaving the cells in a viable state for characterization and growth in culture. The targeted magnetic nanoparticles are fabricated using surface-functionalized super paramagnetic nanoparticles that are encapsulated in a biodegradable and biocompatible polymer to form microparticles. The microparticles are rendered target-selective by additional coatings of gelatin and gold nanoparticles which are derivatized with a targeting ligand specific for a targeted cell type. | 11-05-2015 |
20150316553 | TREATMENT AND DIAGNOSIS OF CANCER - Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. | 11-05-2015 |
20150316567 | METHODS FOR ASSESSING IMMUNOGENICITY - This disclosure relates to methods for detecting the potency of a drug preparation and/or detecting antibodies in a host reactive against one or more antigens. | 11-05-2015 |
20150329829 | METHOD FOR CULTURE OF HUMAN AND MOUSE PROSTATE ORGANOIDS AND USES THEREOF - The invention discloses a methodology for the culture of prostate tissue organoids from mouse and human prostate. | 11-19-2015 |
20150330983 | PEPTIDIC AND NON PEPTIDIC LIGANDS FOR IMMUNODETECTION OF THE RECEPTOR FOR UROTENSIN II - The use of opportunely modified specific ligands of the receptor for urotensin II (UTR) or antibodies (commercially available) raised against the same receptor as tools for the definition of both the differentiation and the prognosis of human prostate adenocarcinoma is described, moreover, the use of opportunely radiolabeled ligands for UTR in the definition of the extension of disease is also described. | 11-19-2015 |
20150337051 | TEM-1 DIAGNOSTIC ANTIBODIES - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample. | 11-26-2015 |
20150338392 | Sterile and instantly dissolvable drug membrane and method thereof for testing drug sensitivity of antineoplastic drugs - A sterile and instantly dissolvable drug membrane, a method thereof for testing drug sensitivity of antineoplastic drugs, and an application thereon in testing drug sensitivity of antineoplastic drugs are provided, wherein the method for testing drug sensitivity of antineoplastic drugs includes steps of: dissolving an antineoplastic drug in a cell culture fluid comprising tumor cells, in such a manner that the antineoplastic drug fully contacts with the tumor cells; wherein the antineoplastic drug is prepared into a sterile and instantly dissolvable drug membrane for being dissolved in the cell culture fluid. According to the present invention, the antineoplastic drug is prepared into a sterile and instantly dissolvable drug membrane for testing drug sensitivity of the antineoplastic drugs, which improves operation efficiency, flexibility, accuracy and economy of drug sensitivity test of the antineoplastic drugs. | 11-26-2015 |
20150344514 | CHEMICALLY CLEAVABLE GROUP - Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactive components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine. | 12-03-2015 |
20150362498 | METHOD OF DETECTING C-MET GENE AMPLIFICATION CELL - The present invention provides a method for detecting a c-MET gene amplification cell. Specifically, the present invention provides a method for detecting a c-MET gene amplification cell, comprising measuring a soluble c-MET in a sample utilizing a region specific for the soluble c-MET, wherein the soluble c-MET is formed by cleavage between the lysine residue (K) and the valine residue (V) in the partial region GKVI (SEQ ID NO:2) in a c-MET extracellular domain. | 12-17-2015 |
20150368356 | TUMOR SPECIFIC ANTIBODIES AND USES THEREFOR - Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject. | 12-24-2015 |
20150369708 | CYTOLOGICAL STAINING COMPOSITIONS AND USES THEREOF - The present subject matter is directed to a composition for staining cytological material comprising a cationic dye component, a hygroscopic polyol and optionally a water-soluble solvent, water or water-miscible solvent, methods of use of the compositions. Advantageously, the present compositions do not require the use of a cover slide as is required in known staining fixatives. The compositions are able to retain cell morphology for a period of time such that a cover slide is not required. Further, the compositions do not contain hazardous levels of organic components. Preferably, the compositions consist essentially of Azure C, glycerol and optionally water. In another aspect, the present subject matter is directed to a method of characterizing a cell sample comprising contacting the cell sample with a composition comprising a dye component and a hygroscopic polyol and subjecting the sample to analysis to determine the presence or absence of abnormal cells. | 12-24-2015 |
20150376566 | Process for the Preparation of Multicellular Spheroids - The invention pertains to a process for the preparation of multicellular spheroids from a suspension of single cells, wherein the cells are directly derived from a biological tissue and/or from cell-containing bodily fluid. The invention is further directed to the multicellular spheroids obtained by the process according to the invention as well as to the use of the spheroids for diagnostic, screening and therapeutic purposes. | 12-31-2015 |
20160003826 | PROCESS FOR DETECTION AND OPTIONAL QUANTIFICATION OF AN ANALYTE - The present disclosure relates to a process for detecting and optionally quantifying an analyte in a sample in the presence of a soluble target of the analyte. The soluble target forms a complex with the analyte and thus may interfere in determining the total analyte concentration. The process of the present invention utilizes a unique modified citrate buffer for diluting the sample containing the analyte and the soluble target which in turn helps in dissociating the analyte-soluble target complex, thereby enabling the process of the disclosure to detect and optionally quantify measure the analyte accurately. | 01-07-2016 |
20160003828 | BREAST-CANCER DETERMINATION METHOD - The present invention provides a breast cancer marker selected from the group consisting of fucosylated hornerin, fucosylated Zn-α-2-glycoprotein, fucosylated Ig γ-1 chain C region, and fucosylated desmoplakin; a method for determining breast cancer comprising detecting the breast cancer marker in a sample, and determining on the basis of the results of the results; and a kit to be used for the determination. | 01-07-2016 |
20160009780 | Gene Expression Control DNA Element and Associated Protein | 01-14-2016 |
20160021872 | URINE PRESERVATIVE REAGENT FOR MICROFILTRATION - A preservative reagent for urine is disclosed that increases the stability of cells, such as tumor cells, in urine for a period of several weeks. The preservative reagent comprises polyethylene glycol (PEG), ethanol, paraformaldehyde (PFA), and ethylenediaminetetraacetic acid (EDTA), and optionally pH stabilizing reagents. | 01-28-2016 |
20160025720 | DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS - The present invention provides a device for isolating target biomolecules or cells from samples, particularly biological samples. In particular, the device comprises a loading mixture, which contains the biological sample and a first binding entity that specifically binds to the target biomolecule or target cell; and a micro-channel coated with a second binding entity that binds directly or indirectly to the first binding entity. Methods of capturing, detecting, and/or evaluating target biomolecules or target cells (e.g. cancer cells) in biological samples are also disclosed. | 01-28-2016 |
20160033485 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS - The present disclosure provides compositions comprising a food product, non-pathogenic microorganism, kits, methods of diagnosing a tumor in a subject, methods of quantifying the number of cancer cells in a cell sample, and methods of detecting a cancer cell, cancer tissue, or cell associated with a hyperproliferative disorder. In some embodiments, the method comprises a step of detecting the presence or absence of a modified substrate or portion thereof in urine of an animal without an instrument and solely by visual inspection of the urine. | 02-04-2016 |
20160033516 | USE OF POLYCLONAL AND MONOCLONAL ANTIBODIES SPECIFIC FOR 3-PHOSPHOHISTIDINE - Isolated monoclonal antibodies and antigen binding fragments are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis), detection of a tumor, monitoring the effectiveness of therapeutic agent, and identifying antibiotics. In some embodiments, the methods can be used to investigate signal transduction pathways. | 02-04-2016 |
20160041153 | BIOMARKER COMPOSITIONS AND MARKERS - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes. | 02-11-2016 |
20160041170 | METHOD FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS - This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide. | 02-11-2016 |
20160047812 | METHOD FOR DETECTING COLON CANCER - A method for detecting a colorectal cancer, including the steps of measuring an amount of exosomes expressing CD147 in a body fluid sample derived from a test individual with an anti-CD147 monoclonal antibody or a fragment thereof; and comparing a signal intensity of exosomes in the step with a signal intensity in a control individual, wherein a case where the signal intensity in the test individual is found to be stronger than the signal intensity in the control individual serves as an index of the presence of the colorectal cancer. According to the method of the present invention, whether or not a sample provider has a high possibility of developing a colorectal cancer can be judged. Therefore, the method is useful because the sample provider can take a means of inhibiting the progression of cancer. | 02-18-2016 |
20160091489 | DEVICES AND METHODS FOR ISOLATING CELLS - The subject invention pertains to devices and methods of isolating target cells from a population of cells. The devices comprise of one or more microfluidic channels and scaffolding particles conjugated with one or more ligands that bind to the target cells. The scaffolding particles with one or more ligands are attached on to the surface of the one or more microfluidic channels. The methods of the current invention comprise passing the population of cells through the microfluidic channels of the devices of the current invention to facilitate interaction and capture of the target cells by the scaffolding particles-ligand conjugates, washing the device by a washing solution to remove the cells non-specifically bound to the scaffolding particle-ligand conjugates, releasing the captured target cells from the scaffolding particle-ligand conjugates, and collecting the released target cells. | 03-31-2016 |
20160103131 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN - ADAM 12 expression and activity are up regulated in patients that have cancers of epithelial origin, such as breast cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, and skin cancer, as well as others: Accordingly. the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. In particular, the presence of ADAM 12 in a biological sample is indicative of cancer of epithelial origin. Further, the amount of ADAM 12 protein detected in biological samples, e.g. urine, correlate with disease status such that ADAM 12 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of ADAM 12 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient. | 04-14-2016 |
20160115229 | Hybridoma Clones, Monoclonal Antibodies, and Methods of Use - The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier. | 04-28-2016 |
20160116478 | REAGENT INCLUDING ANTI-LGR6 ANTIBODIES FOR DETECTION AND DIAGNOSIS OF CANCER - The object of the present invention is to provide a reagent for detection or diagnosis of cancer. | 04-28-2016 |
20160131654 | DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, AND B-CELL NON-HODGKIN LYMPHOMA - The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject. | 05-12-2016 |
20160131659 | FLUORINATED POLYMER DOTS - This disclosure provides semiconducting polymer dots (Pdots) for use in a wide variety of applications. In particular, this disclosure provides Pdots that are halogenated, including fluorinated Pdots. This disclosure also provides methods for synthesizing Pdots and methods for using Pdots, such as for biological imaging. | 05-12-2016 |
20160139131 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Le | 05-19-2016 |
20160145580 | METHOD OF CULTURING CANCER STEM CELLS - There is provided a method for culturing a population of cancer stem cells. The method comprises introducing the cancer stem cells on or in a cell culture substrate, the cell culture substrate being in the form of a gel comprising a conjugate of a glycosaminoglycan and a substituted phenalkylamine. | 05-26-2016 |
20160146783 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION - In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell. In alternative embodiments, the invention provides compositions and methods for determining: whether an individual or a patient would benefit from or respond to administration of a Growth Factor Inhibitor, or, which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice a method of the invention, such as an NFKB inhibitor, such as a lenalidomide or a REVLIMID™, or IKK inhibitor; or an inhibitor of Galectin-3. | 05-26-2016 |
20160146825 | METHOD FOR DETECTING LOW CONCENTRATIONS OF SPECIFIC CELL FROM HIGH CONCENTRATIONS OF CELL POPULATIONS, AND METHOD FOR COLLECTING AND ANALYZING DETECTED CELL - Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable. The identifying and counting step includes evaluating the respective absolute concentrations of live and dead CTCs in a volume of blood by automatically identifying CTCs by the ratio of a plurality of fluorescence signal intensities using a flow cytometer, and differentiating between and counting the live CTCs and the dead CTCs. In the cytometer, an entire liquid-feeding system that includes a flow cell can be replaced for each sample, and the total amount of a liquid sample can be measured. | 05-26-2016 |
20160153999 | SELECTIVE CAPTURE AND RELEASE OF RARE MAMMALIAN CELLS USING PHOTODEGRADABLE HYDROGELS IN A MICROFLUIDIC PLATFORM | 06-02-2016 |
20160154000 | B7-H1 AND SURVIVIN IN CANCER | 06-02-2016 |
20160159925 | ANTI-HUMAN CD26 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF - It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644. | 06-09-2016 |
20160161491 | ACTIVATED HER3 AS A MARKER FOR PREDICTING THERAPEUTIC EFFICACY - The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed. | 06-09-2016 |
20160178630 | METHODS FOR PREDICTING OVERALL SURVIVAL OF CANCER PATIENTS BASED ON NUMBERS OF CIRCULATING TUMOR CELLS | 06-23-2016 |
20160195533 | METHOD FOR SCREENING EMT INHIBITOR | 07-07-2016 |
20160195539 | IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY | 07-07-2016 |
20170234879 | NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER | 08-17-2017 |
20170234883 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | 08-17-2017 |
20180024132 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | 01-25-2018 |
20180024135 | MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOSYSTEMS FOR RAPID TARGETING, ISOLATION, DETECTION AND SIMULTANEOUS IMAGING OF CIRCULATING TUMOR CELLS | 01-25-2018 |
20220137053 | LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING - Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment. | 05-05-2022 |
20220137066 | PHOTOCLEAVABLE MASS-TAGS FOR MULTIPLEXED MASS SPECTROMETRIC IMAGING OF TISSUES USING BIOMOLECULAR PROBES - The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme). | 05-05-2022 |